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ROLE OF PATHOLOGISTS
IN BREAST CANCER UNITS
G. Bussolati
Dept. Biomedical Sciences and Oncology, University of
Turin, Turin, Italy
Pathologists are part of the core team of breast units,
together with surgeons and radiologists. This means that
they do not only play a diagnostic role for breast cancer,
as used in the past, since they are requested for pre- and
postoperative role in planning the therapeutic approach.
Meetings for planning treatment of single cases are of
basic importance, and also as an occasion for other spe-
cialists to understand our problems of morphological in-
terpretation. Such meetings are a stimulus so that patholo-
gists can better afford the new requests imposed by a rap-
idly changing scenario. One of the most compelling re-
quests is reproducibility, and to achieve it pathologists
must confront with diagnostic guidelines, definitions and
landmarks. Guidelines produced by a group established by
the EU of pathologists from different European countries
involved in breast cancer screening proved effective in fa-
voring reproducibility, as expressed by K statistics. How-
ever, in specific areas such as classification and definition
of in situ lesions, such as atypical hyperplasia, reproduc-
ibility is far from ideal. Participation in a breast unit means
highlighting of specific steps, which proved essential in a
collaborative work and, ultimately, for the fight against
breast cancer. Important steps are: identification of micro-
calcifications, definition of margins, diagnosis of in situ
and microinvasive lesions, detection of metastatic spread.
Problems are in fact not only related to morphological in-
terpretations, but to communication as well. Examples are
the diagnostic definition of fine needle aspirates and core
biopsies, where the use of five standard categories (inad-
equate, benign; atypic, probably benign; suspect for ma-
lignancy, malignant) has proved effective in producing a
preoperative diagnosis in conjunction with radiological
and clinical criteria. The management, either cytologic or
histologic of axillary lymph nodes and especially of senti-
nel nodes is a new challenge of both scientific and diag-
nostic impact. Similarly, the evaluation of the prognostic
and therapeutic parameters such as HER2 overexpression/
amplification poses new budgetary problems which have
to be solved by pathologists not only through diagnostic
skill, but on the basis of organization and collaboration as
well.
SOFT TISSUE TUMORS OF THE BREAST
V. Eusebi
Anatomic and Surgical Pathology of the University of
Bologna, Ospedale Bellaria, Bologna, Italy
Benign and malignant soft tissue tumors of the breast
will be presented. Lipomas are the most common benign
soft tissue tumors of the breast. When glandular tissue is
entrapped within a lipoma, the lesion qualifies as adeno-
lipoma or adenohibernoma according to the type of adi-
pose tissue. The first case of angiomyolipoma HMB 45
positive will be illustrated. A unifying concept concern-
ing solitary fibrous tumors, myofibroblastomas and spindle
cell lipomas will be presented. The term of benign spindle
stromal cell tumor (BSST) will be proposed for these le-
sions that are amenable to a common precursor cell of the
breast stroma that is vimentin and CD 34 positive. Ac-
cordingly, the concept of malignant spindle stromal cell
tumors (MSST) will be presented along the line of the
benign counterpart. Angiosarcomas will be discussed with
emphasis on the Stewart Treves syndrome.
MALIGNANT LYMPHOMA OF THE BREAST
J. Lamovec
Institute of Oncology, Ljubljana, Slovenia
Malignant lymphomas of the breast are a rare disease.
They may occur as primary or secondary tumors. Morpho-
logically, it is not possible to determine their primary or
secondary nature1.
The criteria for defining a lymphomatous lesion in the
breast as primary were first proposed by Wiseman and
Liao in 19722: 1) availability of adequate histologic ma-
terial; 2) documentation of breast involvement as a pri-
mary site; 3) presence of breast tissue in or adjacent to
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lymphoma infiltrate; 4) no concurrent nodal disease ex-
cept for the involvement of ipsilateral axillary lymph
nodes; and 5) no previous history of lymphoma involving
other organs or tissues.
Strictly adhering to such criteria, some primary breast
lymphomas may be lost since no allowances are made for
those primary breast lymphoma cases that may present in
higher clinical stages. Obviating this, some authors con-
sider as primary breast lymphomas all those cases in which
breast is the first or major site of presentation even though
subsequent staging procedures reveal involvement of other
sites, such as bone marrow3.
Clinical Presentation
The lesion most commonly presents as a unilateral
breast mass in postmenopausal women (median age 55 to
60 years), although it may occur at any age. In about 10%
of cases, it is bilateral. In men, breast lymphoma is exceed-
ingly rare.
A subset of patients, characteristically from tropical
Africa, are young women, during or immediately after
pregnancy, who present with massive bilateral breast swell-
ing. The latter disease is endemic in this part of the world.
Histologic examination in these patients reveals Burkitt’s
or Burkitt-like lymphoma4. Non-African cases of this type
of lymphoma are also on record.
The incidence of primary breast lymphoma ranges
from 0.04% to 0.5% of breast malignancies in most pub-
lished series 1,3,5 .The incidence of secondary lymphoma
in the breast is difficult to ascertain, since many of those
lesions are but one manifestation of disseminated disease
and are never biopsied.
Gross Features
Primary and secondary breast lymphomas usually
present grossly as a well defined uni- or multinodular mass
of soft or firmer white-gray tissue, sometimes with ne-
crotic and hemorrhagic foci.The tumor varies in size and
may attain up to 20 cm in diameter.
Histopathology
The vast majority of breast lymphomas are diffuse
large cell B lymphomas as defined by recent WHO clas-
sification. The latter lymphomas were given different
names in older classification schemes, such as reticulum
cell sarcoma, histiocytic lymphoma, large cell cleaved or
noncleaved lymphomas, centroblastic or immunoblastic
lymphoma, etc. In addition to large cell B lymphomas, a
variety of other types of lymphoma may also manifest as
primary or secondary tumors in the breast.
The relation of pre-existing mammary tissue and in-
filtrating lymphoma varies. In some cases, the bulk of the
tumor is located in subcutaneous fatty tissue and breast
parenchyma is at its periphery; in other cases, the ducts
and lobules of breast tissue are embedded in the infiltrate,
while in rare cases pre-existent tissue is overgrown by lym-
phoma and barely visible. In such cases, remnants of ducts
and lobules may only be revealed by using keratin
immunostaining. Stroma may be scant or more abundant,
sometimes sclerotic and hyalinized. Although most of the
tumors are grossly circumscribed, a microscopically differ-
ent degree of infiltration of the surrounding tissue is al-
ways evident.
Diffuse large cell B lymphoma1,3,5-8: This type of lym-
phoma is characterized by large lymphoma cells with oval
or indented nuclei, with one to three nucleoli and with
a narrow rim of basophilic cytoplasm; such cells gener-
ally resemble centroblasts. Different number of immuno-
blasts are frequently admixed, sometimes such cells are
predominant. Mitoses are usually numerous. In some
cases, cells appear more pleomorphic with wider varia-
tion in cell forms and sizes; smaller reactive lymphocytes
of B or T types are also present in the infiltrate. Occa-
sionally, reactive histiocytes are numerous, imparting a
“starry sky” appearance to the tumor. Adjacent mammary
tissue may exhibit lobular atrophy or lymphocytic lo-
bulitis which may be very prominent (lymphocytic mas-
topathy).
Lymphoma cells are immunoreactive for CD20,
CD79a, CD45RB, and negative for CD3 and CD45RO.
Cases with immunoblastic features may show light chain
restriction. Exceptionally, lymphoma cells may express
CD30 antigen.
Follicular lymphoma 1,3,5,7,8: It features neoplastic fol-
licles composed of centrocytes and centroblasts in differ-
ent proportions and may be graded into 2 or 3 grades, de-
pending on the number of centroblasts inside the neoplas-
tic follicles. Immunohistochemically, the lymphoma cells
show positivity for B cell antigens, and for CD10 and bcl-
2, and are negative for CD5 and CD23. Follicular den-
dritic cells in tight clusters, positive for CD21, delineate
neoplastic follicles. Selective infiltration of ductal-lobu-
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lar units by lymphomas of other types, such as diffuse large
cell B lymphoma may mimic neoplastic follicles and could
be confounded for true follicular lymphoma.
Burkitt’s lymphoma4,8: The infiltrate in this lymphoma
is composed of medium-sized cells with round nuclei,
multiple central nucleoli, coarse chromatin and rather
thick nuclear membrane. The cytoplasm is moderate in
amount, basophilic with fine vacuoles containing lipids.
Mitoses are very numerous. Cells grow in a cohesive pat-
tern, they square off with each other. Numerous tingible-
body macrophages are evenly scattered among lymphoma
cells producing characteristic but in no way pathogno-
monic “starry sky” appearance of the lymphoma. The
breast parenchyma is usually hyperplastic and secretory.
Ki-67 fraction of viable cells is 100%.
Immunohistochemically, pan-B markers are positive,
surface immunoglobulins, usually of IgM type, are also
positive, while CD5, bcl-2, and TdT are negative. EBV
is frequently demonstrated in endemic but not in sporadic
cases. IgH and IgL genes are rearranged.
Burkitt-like lymphoma is similar in morphological
appearance but immunoblast and centroblast-like cells are
also admixed.
Extranodal marginal-zone B-cell lymphoma of MALT
type1,3,5 : An undetermined number of breast lymphoma
cases belong to the category of MALT lymphoma. The
breast is considered to be part of a common mucosal im-
mune system9 and may, during an autoimmune process,
acquire lymphoid tissue in lymphoma. Most recent series
of breast lymphoma have some cases of MALT lymphoma
included. Typically, lymphoma of this type is composed
of small lymphocytes, monocytoid (marginal zone type)
cells and plasma cells. The latter may dominate the whole
microscopic aspect of the lesion. Larger blast type cells
may also be present. The infiltrate may be vaguely nodu-
lar, reactive follicles may be seen, some of them colonized
by monocytoid cells. The lymphoepithelial lesion, i.e. in-
filtration of the ductal/lobular epithelium by monocytoid
(centrocyte-like) cells was originally overestimated as a
diagnostic criterion for MALT lymphoma of the breast;
its presence is not a prerequisite for diagnosis. Further-
more, it has become increasingly evident that breast epi-
thelium is infiltrated by lymphoma cells of a variety of
lymphomas and even more commonly by T reactive cells
admixed to lymphomatous infiltrate. Immunohistoche-
mically, MALT lymphoma cells express pan-B markers
such as CD20 and CD79a, it is usually bcl-2 positive but
negative for CD10, CD5, and CD23. The translocation
t(11;18)(q21;q21) has been identified in many MALT
lymphomas; analysis did not include breast cases10. The
same holds true for recently described trisomy 3 identi-
fied in a number of MALT lymphomas 11. Breast may also
be involved by secondary MALT lymphoma originating
at another MALT site.
Some other types of lymphoma may also rarely present
in the breast, as primary or secondary lesions, including
lymphoblastic lymphoma of either B or T type, extremely
rarely peripheral T cell lymphoma, and secondary small
lymphocytic lymphoma/CLL or mantle cell lymphoma.
Differential Diagnosis
 Large cell malignant lymphomas may, in certain in-
stances, be misdiagnosed as poorly differentiated duct or
lobular carcinoma. Immunohistochemical reactions for
keratin resolve any possible dilemma in such cases. My-
eloid cell tumors may also be confounded for malignant
lymphomas; if basic immunoreactions are inconclusive,
myeloperoxidase staining to exclude the former possibil-
ity should be used. Inflammatory conditions may mimic
MALT lymphomas; in some cases immunohistochemical
reactions, flow cytometry and molecular genetic analysis
should be employed to determine clonality of the lesion.
Reactive follicular hyperplasia can be differentiated from
follicular lymphoma by using bcl-2 immunoreactions; re-
active follicles are bcl-2 negative. The issue of so-called
pseudolymphoma remains unresolved; many authors be-
lieve that they really represent MALT type lymphoma.
Prognosis and Treatment
Primary breast lymphoma behave in a similar way as
lymphomas of corresponding types and stages in other
localizations. Localized low-grade lesions, such as MALT
type lymphomas, are treated locally by surgery and/or ra-
diation; high grade tumors require systemic chemotherapy
with or without irradiation.
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RECENT ADVANCES IN MOLECULAR
GENETICS OF BREAST CANCER
K. PaveliÊ, K. Gall-Troπelj
Ruer BoπkoviÊ Institute, Division of Molecular
Medicine, Zagreb, Croatia
Breast cancer is among the most common tumors af-
fecting women. It is characterized by a number of genetic
aberrations. Five to 10% of all cases are estimated to be
inherited. The hereditary breast and ovarian cancer syn-
drome includes genetic alterations of various susceptibil-
ity genes, particularly BRCA 1 and BRCA 2. Breast tu-
mors in patients with a germ-line mutations in the BRCA
1 and BRCA 2 gene have an increase in additional genetic
defects compared with sporadic breast tumors. Accumu-
lation of somatic genetic changes during tumor progres-
sion may follow a specific and more aggressive pathway of
chromosome damage in these individuals. Recent ad-
vances in genomics and bioinformatics, particularly in
DNA-sequencing approaches and DNA-chip technology
are revolutionizing target identification of small molecules.
Here we review some new findings in the function of
BRCA 1 gene function. A major BRCA 1 downstream
target gene is the DNA damage-responsive gene GADD
45. Induction of BRCA 1 triggers apoptosis through ac-
tivation of c-Jun N-terminal kinase/stress-activated pro-
tein kinase ( JNK/SAPK). BRCA 1 interacts with the
SWI/SNF complex which controls DNA structure. SWI/
SNF is a chromatin remodeling complex important in
gene expression. New knowledge about the genetic por-
trait of breast tumor is coming from differential gene ex-
pression profiling using microarrays. Human genome
studies as well as development of “DNA chips” provide a
window for observing patterns of gene activity in cells,
which will revolutionize cancer classification. Knowledge
of the molecular characteristics of breast tumor has already
made it possible to identify those breast cancer patients
who could benefit from therapies that target these features.
Progress in basic research in signaling provides the oppor-
tunity to attack signal-transduction targets involved in
proliferation, survival, invasion, angiogenesis, metastasis
and resistance. Exciting knowledge in breast cancer biol-
ogy is rapidly accumulating in parallel with recent devel-
opments in rational selection and validation of relevant
targets that provide unique opportunities for development
of “intelligent” therapeutics.
IDENTIFICATION OF NEW MOLECULAR
TARGETS FOR THE TREATMENT OF
BREAST CANCER
E. A. G. Blomme1, F. Del Piero2, K. L. Kolaja1
1Pharmacia Corporation, Molecular and Experimental
Toxicology and Pathology, Skokie, IL, USA, and
2University of Pennsylvania, School of Veterinary
Medicine, Department of Pathobiology and Department
of Clinical Studies, New Bolton Center, PA, USA
SUMMARY - The completion of the human genome
sequence provides unique opportunities to identify new
molecular targets for a variety of diseased conditions, es-
pecially for neoplastic diseases. Breast cancer is an ideal
disease for the implementation of the recently developed,
sophisticated genomic technologies, which permit the
study of expression of many genes or proteins simulta-
neously, an approach known as molecular profiling. This
approach is considered a major step forward in the devel-
opment of new drugs that are more effective and less toxic
than the current generation of antitumor agents. In this
paper, we briefly review the current and future genomics
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technologies, such as DNA microarrays and proteomics
techniques, and their use in the identification of new
molecular targets for the treatment of breast cancer. We
also discuss the challenge associated with the development
of bioinformatics tools to analyze the massive number of
data points generated by these technologies. Proof of prin-
ciple is now emerging, demonstrating that selective agents
against abnormal or mutated gene products can indeed be
useful in the treatment of cancer. However, despite heavy
investment in genomics research by the pharmaceutical
industry, the full impact of genomics on drug discovery has
yet to be fully demonstrated.
Key words: Genomics; Microarrays; Proteomics; Molecu-
lar target
Introduction
The completion of the human genome sequence pro-
vides a quantum lead towards identifying new molecular
targets for a variety of diseased conditions, especially for
neoplastic diseases1,2. The repositories of genes and their
regulatory sequences represent the starting point of a new
challenge, understanding how the 30,000-40,000 genes
present in the human genome and their protein products
interact and function. In addition of providing the unique
opportunity to better understand basic biology and to
identify the molecular basis of diseases, the annotation of
the human genome offers the promise of an increased rate
of drug discovery and development.
Breast cancer is a major health problem worldwide and
consequently, a large amount of research effort has been
focused on the molecular understanding of this disease3.
The medical treatment of cancer still has many unmet
needs4. The main curative therapies (surgery and radia-
tion) are usually successful only at an early stage, and ex-
isting chemotherapeutic treatments are largely palliative.
The majority of the current antitumor agents have been
unveiled during screening in cytotoxicity assays, although
some have also been designed to act on defined molecu-
lar targets. However, none of the established cancer drugs
were developed in the light of a clear understanding of the
molecular differences between neoplastic and normal cells.
Breast cancer is an ideal disease for the implementation
of the recently developed, sophisticated genomic tech-
nologies, which permit to study the expression of many
genes or proteins simultaneously, an approach known as
molecular profiling. This approach is considered a major
step forward in the development of new drugs that are
more effective and less toxic than the current generation
of antitumor agents. In this paper, we will review the ap-
plication of genomic technologies for the rational identi-
fication of new therapeutic targets for breast cancer.
DNA Microarray and Molecular
Transcription Profiling
Molecular transcription profiling is the large-scale
analysis of gene expression using DNA array technolo-
gies5,6. DNA microarrays have only been recently intro-
duced to the scientific community7. Microarrays consist
of rows and rows of microscopic spots, each of which con-
tains an identical single-stranded polymeric molecule of
deoxyribonucleotide (typically oligonucleotides or
cDNAs, the probe) attached to a solid support, such as a
glass slide or a miniature silicon chip. These arrays can
accommodate up to tens of thousands of spots and can be
used for high-throughput studies of genomic structure and
studies of active gene expression. Figure 1 provides an il-
lustration of these DNA arrays. These arrays use the
principle of specific DNA base pairing, i.e. A-T and G-
C, to allow the large-scale analysis of mRNA abundance
as an indicator of gene expression, to detect polymor-
phisms within a population, or to detect new genes, as
unknown DNA sequences can be analyzed8. Over the past
few years, a number of different commercially available
array products have been introduced. Although most of
these products remain relatively expensive, their cost is
regularly decreasing, and these products should soon be-
come affordable for most laboratories. Therefore, it is criti-
cal that most cancer scientists become familiar with this
technology. Recently, customized or in-house microarrays
have grown in popularity to help investigators focus on
their particular area of interest without being distracted by
the huge volume of data generated by some commercial
microarrays9. It should be mentioned that, although the
microarray technology is the most widely used technique
for gene expression analysis, others are available, includ-
ing serial analysis of gene expression (SAGE) , differen-
tial hybridization, differential display or GeneCalling®10.
The application of arrays to genomic studies includes
the search for single nucleotide polymorphisms (SNPs)
and a powerful application of these studies is in the field
of pharmacogenomics6. Because each individual has a
slightly different genetic makeup, each will have a unique
set of SNPs. SNPs are the most frequent form of genetic
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variation (~3 million/person or approximately 1 SNP/kb),
are highly stable, and are relatively easy to identify. Pro-
grams to detect and map SNPs in the human genome are
well underway with the ultimate aim of establishing a SNP
map of the genome11. When SNP analysis is used in con-
junction with analytical techniques, such as genetic-link-
age mapping or association analysis, a genetic propensity
for predisposition to disease, unique metabolism, or ad-
verse events can be identified.Although these SNPs may
not be the actual cause of disease, their utility lies in their
potential to help predict how an individual may respond
to a particular drug. Pharmacogenomics may, therefore,
help identify at-risk patients prior to treatment and pre-
vent adverse drug reactions. Furthermore, SNPs may be
useful to predict whether a certain drug would be effec-
tive in a patient with a specific disease. Although most
marketed drugs are efficacious in a vast majority of the
patient population, pharmacogenomics offers an oppor-
tunity to resurrect drugs that have been discarded because
of low efficacy or adverse effects in the entire patient popu-
lation. In this regard, pharmacogenomics can undoubtedly
contribute to a better design of clinical trials in the future.
Molecular transcription profiling analyses have already
profoundly enhanced our understanding of many diseases,
Fig. 1. Gene expression analysis using DNA microarrays. In this example, a two-color microarray is used to analyze transcriptional profil-
ing differences between a diseased tissue and its corresponding normal tissue. RNA is extracted from both the diseased and the normal tis-
sues, each RNA is labeled with a fluorescent probe (in this case a red fluorescence probe, Cy5, for the diseased tissue and a green fluorescent
probe, Cy3, for the normal tissue), and both labeled RNAs are hybridized together on the same microarray. Competitive binding to the thou-
sands of probes printed as microscopic spots on a glass slide leads to a differential fluorescence for each spot based on expression levels of par-
ticular genes. For instance, if a particular gene is expressed at higher levels in the normal tissue compared to the diseased tissue, the spot where
the corresponding probe is printed will appear green. In contrast, if a particular gene is expressed at lower levels in the normal tissue, the
spot will be red. Finally, if a particular gene is expressed at similar levels in both tissues, the two fluorescent colors will blend to form a new
color (yellow). DNA microarrays typically accommodate up to tens of thousands of spots and are now routinely used for high-throughput
studies of active gene expression in diseased tissues. This genomics tool enables scientists to identify previously unrecognized therapeutic tar-
gets in a rapid and efficient manner.
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including breast cancer5,12,13. Cell function can be best
understood by determining the transcription level of all
genes in the genome (the transcriptome). The next step for
transcriptional analysis will be the rapid identification and
evaluation of potential therapeutic targets. In cancer, the
accumulation and combinatorial effects of abnormalities,
driving the initiation and progression of cancer, result from
mutations and/or changes in expression level of cancer-
causing genes14. Therefore, therapeutic agents that would
target the key molecular abnormalities that lead to malig-
nant progression, have the potential of being more selec-
tive than the current non-specific cytotoxic agents, and
therefore, more efficacious and less toxic. Proof of principle
is now emerging that these selective agents can indeed be
useful for the treatment of cancer14. For instance, the HER-
2/neu oncogene is overexpressed in approximately 30 per-
cent of breast cancers, and these tumors are more aggres-
sive and somewhat more resistant to chemotherapy than
those not overexpressing the oncogenes15. These observa-
tions have led to the development of a monoclonal antibody
(Herceptin® or trastuzumab) against the extracellular do-
main of this receptor tyrosine kinase4. Several clinical tri-
als have demonstrated an improved response rate, a prolon-
gation of the time to disease progression, and an increased
Fig. 2. Validation of a molecular target by radioactive in situ hybridization. A critical step after the identification of a putative therapeutic
target is to validate the target’s relevance to the disease process. In this example, a specific mRNA (product of gene X) was shown to be
upregulated 5-fold in a neoplasm compared to normal tissue using DNA microarrays. This gene was, therefore, considered a putative thera-
peutic target. Since no commercial or proprietary antibodies were available against the protein products, radiolabeled riboprobes specific for
this mRNA were generated by in vitro transcription after cloning of the cDNA. These riboprobes were used to evaluate expression of this
gene product in tissue sections. In this particular example (a breast tumor), the gene appears to be up-regulated and specifically expressed in
endothelial cells, suggesting that this gene product may be involved in angiogenesis. Further validation work, using in vitro transfection
experiments, confirmed the role of this gene product in angiogenesis.
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overall survival compared to the standard of care, demon-
strating the power of this genes-to-drugs paradigm for drug
discovery.Herceptin® was approved by the U.S. Federal
Drug Administration (FDA) in 1998 for the treatment of
HER-2-positive breast cancer. Other receptor tyrosine ki-
nases are frequently overexpressed in cancer. Therefore, sev-
eral epidermal growth factor (EGF) receptor tyrosine ki-
nase inhibitors, such as ZD-1839 (Iressa®), are currently be-
ing developed for the treatment of various cancer types, and
results of preclinical studies and preliminary clinical trials
indicate that the EGF receptor is indeed a valid target for
anticancer therapy16,17. Because microarray technologies ex-
amine the expression profile of thousands of genes simul-
taneously at the mRNA level, it is now possible to study the
sum total differences in gene expression between normal
and diseased cells. This clearly will lead to the identifica-
tion of new subtypes of tumors and will not only help the
pathologist provide a more refined biological-based diag-
nosis, but will also enable scientists to identify previously
unrecognized therapeutic targets in a rapid and efficient
manner9,13,18.
Proteomics
A major limitation of transcript profiling is that tran-
scriptional activity does not necessarily reflect the activ-
ity of the protein product of a particular gene. This is
mostly due to variation in cellular location and to com-
plex and versatile protein regulation mechanisms, such as
context-dependent post-translational phosphorylation,
sulphation and glycosylation5. In addition, assigning a role
for a protein based on a gene sequence information is not
always feasible, because gene sequence reveals little infor-
mation about protein function and disease relevance19.
Therefore, a recent focus has been shifted towards pro-
teomics, a protein-based approach to provide functional
and expression information for proteins on a genome-wide
scale (the proteome).
Currently, the proteomics tools consist mostly of elec-
trophoresis or chromatography coupled with mass spec-
trometry19. Several new technologies have recently been
introduced for high-throughput protein characterization
and discovery, such as protein arrays and proteome-scale
screens for generic enzyme activities (e.g., protease and
phosphatase)19. Applying these technologies to various
diseases, and to breast cancer in particular, can work in
concert with genomic technologies to identify new poten-
tial therapeutic targets. The challenge facing proteomics
is, however, enormous, since it is estimated that approxi-
mately 75 percent of proteins in multicellular organisms
have, as of yet, no known cellular function. Furthermore,
human genes are fairly complex, incorporating variable
numbers of protein domains into sophisticated functional
products, with further protein diversity provided by alter-
native splicing17. Finally, protein-based technologies are
extremely low throughput and more challenging to de-
velop compared to transcription profiling techniques.
Laser Capture Microdissection
Genomic and proteomic analysis of cells in their native
environment can provide the most accurate picture of the
alterations that occur in vivo during the disease state. In
vitro, cells are not subject to the endocrine and paracrine
signals that regulate their overall behavior. However, study-
ing tissues is not an easy task, mostly because tissues are
complex three-dimensional structures, composed of large
numbers of perpetually interacting cell populations. In the
case of breast cancer, neoplastic cells may only account for
a small proportion of the tissue analyzed, and the overall
genomic and proteomic analyses may be confounded by the
presence of large numbers of non-neoplastic cells, such as
fibroblasts, endothelial cells or macrophages.
To overcome these confounding factors, powerful ana-
lytical algorithms have been developed to gauge the rela-
tive abundance of an unknown cell subpopulation within
tissue samples. Such algorithms use known genes associ-
ated with particular subpopulations of cells as reference
values to estimate the proportion of cancer cells, stromal
cells and inflammatory cells5. An alternative to the use of
these algorithms is the implementation of microdissection
techniques. Laser capture microdissection (LCM) is a
technology for rapid and easy procurement of a micro-
scopic and pure cell subpopulation from its complex tis-
sue milieu12. The advantage is that LCM permits the in-
vestigator to focus directly on the disease subpopulation
or compare several subpopulations of tissue cells from the
same patient’s sample. In addition, recent data suggest that
LCM would allow quantitative gene expression analysis
in formalin-fixed, paraffin-embedded tissues, allowing to
take advantage of large numbers of archived pathological
tissue specimens20. The disadvantages of LCM are that it
is resource intensive and provides only limited amounts of
cellular material to study, although the recent development
of reliable amplification protocols has partially solved this
problem12. LCM has been successfully applied in the study
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of breast cancer pathogenesis and the identification of po-
tential therapeutic targets, and it is likely that this tech-
nology will become a necessary component of the drug
discovery process, as well as the cancer biology laboratory.
Target Validation
A critical step after the identification of a putative
therapeutic target is to validate the target’s relevance to the
disease process21. An important part of this validation step
can be achieved through the development of appropriate
preclinical animal disease models. In particular, scientists
now have the ability to genetically manipulate the mouse
through transgenesis and gene targeting to test hypoth-
eses regarding gene function and their role in disease.
These knockout or transgenic mouse models (an impor-
tant part of functional genomics) provide a powerful tool
to the gene-to-drug paradigm for drug discovery22. The
literature contains an enormous number of examples
where a genetically engineered mouse model has helped
better define the relevance of a specific gene product in a
disease model. For instance, p53 knockout mice rapidly
develop neoplasms in various tissues, as seen in patients
with the Li-Fraumeni syndrome who have germline mu-
tations of p5323-25. Other molecular tools are also avail-
able for target validation in animal models, such as
antisense oligonucleotides, ribozymes and neutralizing
antibodies4,26.
Another method used to validate a target for breast
cancer is analysis of its expression in a large population of
breast tumors by immunohistochemistry and/or in situ hy-
bridization10. While such a validation step can still be
achieved analyzing one slide at a time, this can be very
tedious and laborious. Hence, the recent development of
tissue microarrays to increase the throughput of the pro-
cess27. Tissue microarrays consist of hundreds to thou-
sands cylindrical tissue biopsies, ranging from 0.6 up to 4
mm in diameter, each from a different patient, all distrib-
uted on a single glass slide. The tissue microarray technol-
ogy has been tested and validated in several cancer types,
including breast cancer28. The data confirmed many of the
clinicopathological correlation of gene amplifications or
immunostaining reactions reported with conventional
techniques on the basis of whole tumor analysis5. Full
automation of tissue array creation and screening is being
developed to expeditiously validate the large numbers of
newly identified potential therapeutic targets for cancer
treatment.
Bioinformatics
While the cancer biologist will definitely benefit from
these new technologies, it is clear that one of the major
current challenges is to develop informatics techniques
to facilitate the processing and analysis of this large
amount of data. Interpretation of data and the develop-
ment of models that facilitate the understanding of spe-
cific biological phenomena have become priorities. A
common characteristic of contemporary drug discovery
projects is their increasing complexity compared to the
past, where discovery efforts were largely dominated by
chemistry and pharmacology. Genomics techniques have
led to the creation of a new research discipline, called
bioinformatics.
Initially, the focus of bioinformatics was on the analy-
sis, processing, and archiving of genomic sequence data.
Because of the rapid progress of the large-scale genome
sequencing projects culminating in a “first draft” of the
human genome, bioinformatics is now moving from the
genome to the transcriptome and proteome level, with
the focus shifting from the evaluation and annotation of
genomic sequence data to the analysis of actual gene
products29. The use of DNA microarrays generates a
massive number of individual data points, which must
then be analyzed by using data mining tools sufficiently
sophisticated to categorize all these data group them in
a meaningful manner8. These analytical tools are aimed
toward the hunting of potential drug targets, the deci-
phering of possible cellular pathways, and the generation
of hypotheses regarding the potential roles of certain
genes. Protein-focused bioinformatics efforts aim to bet-
ter understand the cellular expression, post-translational
modifications, family relationships, structures and func-
tions of proteins, as well as to evaluate their potential as
suitable drug targets29.
Several private and public databases exist for genome
mapping, nucleic acid and protein sequences, and protein
structures. In particular, Internet resources provide invalu-
able information and make available databases with rel-
evance to drug discovery and genomic technologies21. For
instance, the DNA sequence information available in these
public databases can be used to identify transcripts differ-
entially expressed in normal breast epithelial cells and breast
tumor cells30. Similar approaches can easily be adapted and
applied to other tumor types with sufficient transcript se-
quences available in the public databases.
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Conclusion
In drug discovery, initial expectations of new technolo-
gies are often too high. Despite large-magnitude efforts
and resource commitments to new technologies (such as
high-throughput screening and combinatorial chemistry)
in the last decade, our ability to produce high-quality drug
candidates has not become significantly enhanced. Obvi-
ously, the long period of time it takes for novel drugs to
reach the market makes it very difficult to assess the im-
mediate impact of a technology. In the 1990s, the primary
goal of genomics research in the pharmaceutical industry
was to increase the number of identified molecular targets
and to gain proprietary rights to use those targets31. This
goal has partly been successful: many more targets have
been identified, intellectual property abounds, and proof
of principle that these targets are valid has been demon-
strated. However, an increased productivity of the phar-
maceutical industry has yet to be demonstrated. Will
genomics have its expected impact on drug discovery?
First, it is important to remember that these technologies
add a substantial new level of complexity to the drug dis-
covery process, which will require the formation of large
multidisciplinary teams to properly integrate these tools
in the existing drug discovery and development process.
In addition, in the drug discovery and development pro-
cess, a long road with many hurdles separate the identifi-
cation of a relevant gene target and the regulatory approval
of an innovative drug: is the new gene a drugable target?
Can adequate pharmacokinetic properties be achieved?
Does the drug modulate the target in patients? Are there
side effects and if so, are they manageable? Is there sig-
nificant therapeutic benefit? What biomarker can be used
to quickly predict efficacy? Are combinatorial genome-
based therapies necessary for efficacy? What is the appro-
priate patient population? While drug development has
not become much easier or faster, the promise of a major
impact of genomics on drug discovery is still largely in-
tact: it is likely that the genomics technologies will pro-
vide scientists with a large new collection of molecular
targets for the treatment of various diseases, including
breast cancer. However, success will require the proper and
effective use of complementary technologies, expertise and
innovative design of clinical trials, and proper integration
of these various aspects is likely to become the definitive
competitive advantage to pharmaceutical companies.
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PROGNOSTIC VALUE OF HER-2/NEU IN
BREAST CARCINOMA PATIENTS
J. JakiÊ-RazumoviÊ
University Department of Pathology, Zagreb University
Hospital Center, Zagreb, Croatia
The development and spread of malignant tumors is
a multi-step process, involving a variety of alterations in
the mechanisms controlling cell proliferation, differentia-
tion and genetic alterations. Understanding of the biologi-
cal process involved in tumorigenesis has practical appli-
cation in the clinical areas of diagnosis, prognosis and
treatment1,2. The goal of clinicians managing patients with
malignancy is to create therapy to give maximum benefit
to each individual patient. The decisions are usually based
in part on predictors of the likely biological behavior of a
given tumor. The major tumor characteristics in breast
cancer known to be of value in prognosis include tumor
size, tumor histologic type and grade, axillary lymph node
status, steroid hormone receptor status, ploidy, and cell
kinetics3,4. Establishing prognosis based on these param-
eters is successful to a large extent, but they still fail to
accurately predict the clinical course of all patients. There-
fore, the search for better means of integrating prognos-
tic data and for new prognostic markers in breast cancer
patients still remains a major goal.
The human epidermal growth factor receptor-2
(HER-2) protooncogene encodes 185 transmembrane
glycoprotein, often simply calledHER-2/neu or c-erbB-
2 protein receptor. In vitro and animal studies have indi-
cated that HER-2/neu gene amplification and protein
overexpression play a role in oncogenic transformation,
tumorigenesis and metastasis. Furthermore, the growth of
tumors and human breast carcinoma cell lines over-
expressing HER-2/neu receptor is inhibited by anti-
HER-2/neu monoclonal antibody, opening a new avenue
for targeted cancer therapy. In 1987, Slamon et al.6 first
reported a significant relationship between amplification
of the HER-2/neo oncogene and adverse clinical outcome
in patients with breast cancer. Although subsequent stud-
ies have largely confirmed this association in patients with
node positive disease, whether or not HER-2/neo gene
amplification or overexpression is an independent prog-
nostic factor in patients with node-negative breast cancer
remains a matter of controversy5-10. Although still some-
what controversial, the majority of clinical studies suggest
that HER-2/neu is amplified and overexpressed in ap-
proximately 20%-30% of breast carcinomas, and that
among the new biological indicators of tumor aggressive-
ness it is potentially useful in predicting the outcome of
patients with breast carcinoma and can be used effectively
to improve the identification of high-risk patients6,7,11,12.It
is generally accepted that HER-2 overexpression is asso-
ciated with shorter overall survival, low level of ER, and
higher tumor grade.However, considerable variation in the
incidence of amplification/overexpression and prognostic
significance of HER-2/neu has been reported. Some in-
vestigators found amplification in only 10% of patients
and no correlation to clinical outcome13, whereas others
found overexpression in up to 50% of patients and a strong
association with outcome4-14. Indeed, in our study the
incidence of HER-2/neu overexpression was 42.7% with
some marginal association with outcome in univariate
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analysis (p=0.059) and no significant influence on survival
in multivariate analysis15. Conflicting results of numerous
studies, including our study, highlight some of the persist-
ing controversies surrounding the use of HER-2/neu as a
prognostic marker. Also, these results emphasize the im-
portance of considering HER2/neu status in the light of
information provided by other prognostic variables. For
this reason, we tried to assess the prognostic significance
of HER-2/neu overexpression in association with other
known prognostic factors, and showed association with
tumor size (p=0.041) and grade (p=0.037), DNA ploidy
(p=0.046) and cathepsin D expression in stromal mac-
rophages (p=0.024). These findings pointed to HER2/neu
overexpression as an indicator of prognosis in grade II
breast carcinoma, suggesting that determination of both
tumor size and DNA ploidy in combination with HER-
2/neu overexpression appear to enhance the ability to rec-
ognize the patients at different risk15.
More recently, there has been considerable interest in
the potential role of HER-2/neu gene amplification and
overexpression as a predictor of response to various thera-
peutic modalities in patients with breast cancer. In particu-
lar the results of recent clinical trials have indicated that
treatment with monoclonal antibody to HER-2/neu pro-
tein (Herceptin®) may be useful in prolonging the survival
of patients with metastatic disease. In our small group of
17 advanced breast carcinoma patients who were enrolled
in the study from the beginning of 1999 until July 2000
at the Zagreb University Hospital Center, all were treated
with Herceptin® and Taxol® in combination. All patients
had tumors positive for HER2/neu by HercepTest. Par-
tial response to therapy was observed in 47%, stable dis-
ease in 29% and progression of disease in 24% of patients.
However, complete response was not observed in the in-
vestigated group of patients. In this way, the overall
therapy benefit (stable disease and partial response) was
found in 76% of patients. Complications of therapy in-
clude neutropenia, thrombocytopenia, diarrhea and ony-
cholysis, but there were no signs of congestive heart fail-
ure16.
Furthermore, some studies have indicated that tumors
with HER-2/neu overexpression may show resistance to
certain forms of cytotoxic therapy and sensitivity to oth-
ers. Finally, some recent experimental and clinical stud-
ies have suggested that HER-2/neu overexpression is as-
sociated with resistance to tamoxifen even when tumors
were ER positive, and therefore the success of Herceptin®
therapy depends upon the selection of the most appropri-
ate patients for treatment. Candidates for Herceptin®
therapy can be identified by the evaluation of tumor cells
for the presence of altered HER-2/neu.
As a result of this information, there is a growing clini-
cal demand for HER-2/neu analysis of current and
archived breast cancer specimens. There are a variety of
methods available to determine the HER-2/neu status of
breast cancers. These include assays to evaluate: 1) gene
amplification as Southern blot, slot blot, dot blot, poly-
merase chain reaction (PCR), in situ hybridization and
fluorescence in situ hybridization (FISH), 2) assays to
determine mRNA overexpression such as Northern blot
analysis, slot blot, and in situ hybridization, and 3) meth-
ods to assess protein overexpression (Western blot analy-
sis, immunoassay, and immunohistochemistry (IHC).
Many of these methods are beyond the scope of most
pathology laboratories for technical reasons. Furthermore,
most of these assays require prospective collection of fresh
tissue and are not applicable to archival material. The IHC
method performs well and gives a clear picture of the het-
erogeneity ofprotein expression in tumor cells; it distin-
guishes tumor cells from normal cells and is easy to per-
form on routine paraffin-embedded material. HercepTest
is a semi-quantitative IHC assay to determine HER-2/
neu protein overexpression in breast cancer tissues rou-
tinely processed for histologic evaluation. For the deter-
mination of HER-2/neu protein overexpression, only the
membrane staining intensity and pattern should be evalu-
ated using scale 0-3+. Even if the standardized HER-2/
neu protocol is followed, the subjective nature of histologic
scoring can lead to spurious results. The need to distin-
guish between “faint” and “weak” staining is subject to bias
even when positive control tissues are included in each
stain run.Based on the problems associated with IHC (i.e.
lack of standardization and subjective bias), some experts
argue that FISH is a better alternative. FISH measures
HER-2/neu gene amplification but tends to be more ex-
pensive, complicated, and time-consuming than IHC, and
HER-2/neu must be scored on the invasive component of
breast cancer (because a high % of breast in situ lesions
have altered the HER-2/neu status).
Although each of these methods has its advantages and
disadvantages, direct comparisons of these two assays have
been few and are limited by small numbers of cases. Util-
ity of IHC versus FISH for the selection of breast cancer
therapy requires thorough analysis of the results of clini-
cal trials now underway that address this issue. Any cor-
relative study comparing IHC with FISH without statis-
tically significant outcome data of patients treated with
Herceptin® is of limited value for resolving the IHC-
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FISH controversy. Wang et al.17correlated IHC results
with FISH over the past 18 months. These results shoved
excellent correlation in over 98 percent of HercepTest-
negative cases (0, 1+) lacking HER-2/neu gene amplifi-
cation, and in tumors with high expression (3+) demon-
strating amplification. A poor correlation was found be-
tween cases considered to be weakly positive (2+) with the
HercepTest and amplification with FISH. However, only
11 percent of all breast cancer cases demonstrated 2+ IHC
staining. Based on these results, the authors suggest that
clinically and economically, significant value is testing for
HER-2/neu by HercepTest (IHC) with reflex to FISH
only in cases of weakly positive results (2+). The cost of
reflex testing of all 0 or 1+ cases is significant, since this
group comprises up to 88 percent of all breast cancer cases.
Controversy still exists as to whether the cases that show
0 or 1+ staining but demonstrate amplification (two per-
cent of all cases examined) will respond to Herceptin.
In our hands also HercepTest provides excellent repro-
ducibility and standardization, and close to 90% of all breast
cancers can be adequately and reliably determined by IHC,
with molecular evaluation reserved for borderline cases. Our
own findings in 45 patients tested by IHC and FISH for
HER-2/neu detection showed excellent correlation be-
tween IHC HER-2/neu analysis and the molecular tech-
nique for HER-2/neu amplification (FISH), except for the
weakly positive (2+) IHC results as determined by the
FDA-approved HercepTest. By IHC 12/45 (26.6%) were
HER-2/neu positive. Six out of seven IHC high positive
specimens (3+) showed gene amplification by FISH
(85.7%), and 3/5 IHC medium positive specimens (2+)
showed no gene amplification (60%). None of the cases
negative by IHC showed expression of HER-2/neu by
FISH. Concordances between FISH and IHC results were
seen in 42 out of 45 cases (93.5%). We conclude that all 2+
IHC cases can in turn be subject to FISH analysis to con-
firm the presence of an altered HER-2/neu gene. This com-
bination of assays would help ensure that patients who are
most likely to benefit from Herceptin are identified. FISH
testing is used to determine HER-2/neu status in equivo-
cal circumstances, but the use of HercepTest as a screening
assay allows for improved cost control and turnaround time
without detriment to the patient.
It is known that the FISH procedure required more
technician time and more interpretation time per case for
the pathologist than IHC. Reagent costs were subse-
quently higher for FISH than for IHC. There is a high
level of correlation between FISH and IHC in the evalu-
ation of HER-2/neu status of breast cancers using forma-
lin-fixed, paraffin-embedded specimens, although the
choice of which assay to use should be left for individual
laboratories to make based on technical and economic
considerations. The results published to date may make it
difficult to justify the routine use of FISH for detection
of HER2 status in breast cancers18-20. It is generally ac-
cepted, at this level of knowledge that the best approach
is to combine both IHC and FISH assays, and to use the
IHC assay as a triage step, followed by FISH to analyze
the IHC medium and high positive cases18-20.
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FACTORS INFLUENCING PROGNOSIS AND
SURVIVAL IN EARLY (TN0M0)
BREAST CARCINOMA
S. FrkoviÊ-Grazio
Institute of Oncology, Ljubljana, Slovenia
Carcinoma of the breast is the most common malig-
nant tumor in women in the western world. Its incidence
has been rising steadily over the past decades. Despite
considerable progress in early diagnosis and treatment,
mortality remains relatively high and approximately every
third or second woman with breast cancer will ultimately
die of the disease.
TNM stage is generally accepted as the most impor-
tant determinant of outcome in breast cancer. In addition
to hormonal status of the patient (pre- or postmenopausal)
and the presence of steroid receptors in the tumor, TNM
stage has long been the only factor used by clinicians to
make therapeutic decisions.
During the past two decades, there has been a gradual
change in the treatment of breast cancer with a tendency
toward less radical surgery and more adjuvant systemic
therapy. In the early era of chemotherapy, this type of
treatment was mainly used in patients with advanced dis-
ease; however, meta-analyses of large clinical trials have
clearly shown that systemic chemotherapy and hormonal
therapy also reduce the risk of cancer recurrence and mor-
tality in patients with early breast cancer. Accordingly, the
question of who should be treated by systemic therapy has
eventually changed to the question of who should not be
so treated.
Due both to more widespread public education and to
early diagnosis by mammography screening programs, the
percentage ofpatients with node negative breast cancer (N0)
is increasing. The majority of these patients (about 70%) do
not experience disease recurrence after surgery and/or ra-
diotherapy alone (local therapy); therefore, it seems inap-
propriate to suggest systemic adjuvant therapy for all node
negative breast cancer patients. Since the relative risk reduc-
tion is constant across different tumor stages and risk
groups, it is obvious that the absolute benefit from adjuvant
therapy may be quite small in some specific low-risk group
of patients. It is reasonable to attempt to avoid excessive
treatment morbidity and cost by using selective prognostic
markers to identify prognostically relevant subsets of pa-
tients. However, an “ideal” prognostic indicator or a widely
accepted combination of markers able to identify patients
at low versus high risk has yet to be clearly defined.
Numerous studies have reported that several clinico-
pathologic features have prognostic importance in node-
negative breast carcinoma patients. These features include
tumor size, histologic grade, and histologic type of tumor,
vascular invasion and some new biological markers. Only
a few studies have simultaneously evaluated the relative
prognostic weight of various newer biological markers
compared with all conventional clinicopathological mark-
ers by performing a multivariate analysis. Also, the ma-
jority of these studies included heterogeneous group of
patients regarding tumor size.
Recently, an International Consensus Panel proposed
a 3-tiered risk classification for patients with negative
axillary lymph nodes (Table 1) and defined the low-risk
group as those with tumor size of 1 cm or less, positive ER
or PR status and histologic grade 1; they suggested that
this is the only group in which adjuvant systemic therapy
could be omitted. Since this proposal is not based on mul-
tivariate analyses of large data sets, its true prognostic value
remains uncertain.
Table 1. Risk categories for women with node-negative breast cancer
Low-risk Intermediate-risk High-risk
(has all (between the other (has at least
listed factors) 2 categories) 1 listed factor)
Tumor size ≤ 1cm 1-2 cm > 2cm
ER or PR status positive positive negative
Tumor grade grade 1 grade 1-2 grade 2-3
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Although the patients with stage I (T1N0M0) breast
carcinoma (i.e. tumor measuring 2 cm or less without re-
gional lymph node and distant metastasis) have an excel-
lent short term prognosis, approximately 20% will even-
tually develop distant metastases and die of the disease.
However, the remaining majority would be cured by sur-
gery alone and gain no benefit from adjuvant systemic
therapy. Unfortunately, there is no general agreement how
to best identify the latter group.
Less than 15 published studies evaluated the prognos-
tic value of different factors in T1N0M0 breast carcinoma
and only few of them included the newer biologic indi-
cators, such as c-erbB-2, p53, bcl2, Ki67 (MIB-1), flow-
cytometric DNA ploidy or S-phase fraction determina-
tion. Although the results of these studies are somewhat
controversial, histologic or nuclear grade, proliferative ac-
tivity (as assessed by either mitosis counting, SPF deter-
mination or Ki67 expression), vascular invasion and tumor
size most often emerged as significant prognostic factors.
We recently investigated a group of 270 patients with
T1N0M0 breast carcinoma who were treated at the Insti-
tute of Oncology Ljubljana and were followed for a median
of 12.5 years. All original slides were reviewed and exam-
ined for histologic type, mitotic index (MI), Nottingham
histologic grade (NHG) and its components (extent of tu-
bule formation, pleomorphism, mitotic counts) and pres-
ence of vascular invasion. Representative tumor slides were
stained immunohistochemically for p53, bcl-2, c-erbB-2,
MIB-1(Ki67), CEA, ER and PR using LSAB method and
Dako TechMate 500 automatic immunostainer. The prog-
nostic value of investigated features was evaluated using
univariate and multivariate survival analysis.
Survival of our patients (84.4% cancer-specific survival,
CSS, and 77.4% metastasis-free survival, MFS, at 10 years)
was similar to that reported in other series of patients with
T1N0M0 tumors. In keeping with other reports, late re-
currences were not uncommon. The prognostic value of
tumor size was not confirmed in our study: although sur-
vival was somewhat worse in patients with tumors larger
than 1 cm (T1c) than in those with tumors measuring 1 cm
or less (T1ab), the difference was not significant. We con-
firmed the prognostic significance of NHG: both MFS and
CSS were significantly better in patients with grade 1 than
in those with grade 2 or 3 tumors. Apart from NHG, in
univariate analysis, MI, vascular invasion and c-erbB-2 ex-
pression were significant predictors of MFS and CSS. In
addition, CEA expression and MIB-1 reactivity were sig-
nificantly related to MFS, and histologic type to CSS. Age,
menopausal status, type of treatment, PR or ER status and
expression of bcl-2 or p53 were not significantly associated
with survival. The relative importance of prognostic vari-
ables was tested in Cox’s proportional hazard model. When
all variables were entered in the model, MI, histologic type,
vascular invasion and CEA expression emerged as signifi-
cant independent prognostic factors for both MFS and
CSS.
MI was the single most important prognostic factor for
MFS and CSS; however, our findings suggest that optimal
cutoff values for different prognostic groups may be lower
than those proposed in NHG. When testing various mul-
tivariate models to predict CSS, NHG retained its indepen-
dent prognostic value only in the model that did not include
MI and histologic type, whereas it was replaced by MIB-1
reactivity in multivariate analysis of MFS.
By combining four independent factors (MI, histologic
type, vascular invasion and CEA expression) into a prog-
nostic index, the patients could be allocated into three
prognostic groups. Patients in the first group (15%) de-
veloped metastatic disease in almost one half of cases and
those in the second (60%) in one third of cases. In the third
group (25%), prognosis was excellent, with more than 90%
MFS at 15 years after surgery. In the latter group, the use
of adjuvant chemotherapy may be unnecessary. By apply-
ing the aforementioned Consensus Panel criteria, the
group of patients in whom adjuvant systemic therapy
could be omitted would be considerably smaller.
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ADVANCES IN BREAST FNA
F. Schmitt
Instituto de Patologia e Imunologia Molecular da
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Medicina da Universidade do Porto, Porto, Portugal
Fine-needle aspiration cytology (FNA) is a simple,
rapid, accurate and cost-effective method that has become
a standard of care in the evaluation of breast lesions. Over
recent years, FNA has become the method to assess pal-
pable and non-palpable breast lesions, and contributes to
management decisions at surgical and medical levels, be-
ing the source of primary diagnosis in several cases. In
addition, cytology is also largely used to diagnose lymph
node metastasis and to evaluate pleural effusions in pa-
tients with breast cancer. As the treatment planning is fre-
quently made preoperatively based on cytological mate-
rial, the diagnosis should be as precise as possible, and as
much prognostic information should be gained from the
cytologic specimens as possible.
FNA has largely replaced frozen sections and, in cases
candidates for primary chemotherapy it can provide hor-
monal assessment as well as other useful parameters rel-
evant for the prognosis and prediction of therapeutic re-
sponse. Furthermore, FNA material can also be used for
some special studies such as immunohistochemistry,
cytometry, in situ hybridization and molecular biology
techniques.
The aim of this review is to report the major applica-
tion of the new technologies in cytologic material obtained
from breast FNA biopsies.
Identification of Myoepithelial Cells
The presence of myoepithelial cells is one of the most
important criteria to support a diagnosis of benign lesion
in FNA of the breast. However, on cytologic examination,
the correct identification of myoepithelial cells is some-
times difficult, as they might be confused with apoptotic
cells, stromal cells, and even epithelioid histiocytes. Since
some years ago, several markers have been used in cyto-
logic material in an attempt to identify myoepithelial cells.
However, most of these markers (such as smooth-muscle
actin, calponin, H-caldesmon, cytokeratins 5/6/14) have
shown cross-reaction with other cells (myofibroblasts, lu-
minal cells, stromal cells, pericytes) and are expressed at
the cytoplasm of myoepithelial cells that can be lost in
smears.
Recently, two novel markers have been used to iden-
tify myoepithelial cells at the histologic and cytologic lev-
els. P63, a p53-homologue nuclear transcription factor, is
a protein that is necessary for the maintenance of the basal
compartment of several multilayered epithelia and is se-
lectively expressed in basal cells of stratified epithelia, in
the basal cells of prostate and myoepithelial cells of the
breast, salivary and lacrimal cells. Recently, Barbareschi et
al. and our group have shown that p63 is a reliable myo-
epithelial cell marker in histologic sections. Moreover,
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some preliminary studies have pointed out that p63 could
be better than other conventional myoepithelial cell mark-
ers because, as it is localized in the nuclei of myoepithe-
lial cells, it overcomes the cytoplasmic fragility of myoepi-
thelial cells in FNA. Studying more than 90 cases of breast
FNA smears with immunocytochemistry for p63 antibody,
we demonstrated that this marker highlighted the nuclei
of two distinct cell populations: 1) all of the oval-to-
spindle-shaped cells with dark nuclei on epithelial cell
clusters, and 2) all of the naked nuclei observed in the
background of the smears. No immunoreactivity for p63
was observed in the cells admixed with fibrillary matrix
of fibromyxoid stroma or in those isolated cells with oval
nuclei and sparse-to-moderate cytoplasm. Based on these
results, we strongly suggest that p63 is a reliable marker
for myoepithelial cells in breast FNAs and that the ma-
jority of naked nuclei, defined as oval-to-spindle-shaped
cells without any discernible cytoplasm, show a myoepi-
thelial origin and thus, they might be included in the
major criteria to diagnose benign breast lesions. Moreover,
we observed that p63 helps identify myoepithelial cells
overlying malignant cell clusters that we found consis-
tently in cases of ductal carcinoma in situ. However, fur-
ther studies with large series of patients using similar
methodology are required in order to define how specific
and sensitive this finding is in ruling out invasion in FNA
of the breast.
The other myoepithelial cell marker used by our group
is maspin. Maspin is a member of the serpin family of
serine protease inhibitors, and it has been claimed to be a
tumor and metastasis suppressor and to have anti-
angiogenic properties. Maspin is consistently expressed by
myoepithelialcells and our group has shown that myoepi-
thelial tumors of the breast are positive for maspin. Al-
though initial studies demonstrated cytoplasmic expres-
sion only, we showed for the first time that maspin is also
expressed in the nuclei, a finding recently confirmed by
other groups.
Estrogen and Progesterone(ER/PR) Assessment
Besides giving prognostic information, hormonal re-
ceptor analysis is a useful tool to predict hormonal re-
sponse in human breast cancer. According to the College
of American Pathologists (CAP) Consensus Statement
1999, concerning the prognostic factors in breast cancer,
hormone receptor analysis should be performed routinely
in all primary breast carcinomas. Although hormone re-
ceptor analysis has been traditionally performed on sur-
gically removed specimens, FNA offers a suitable alter-
native for this determination in a number of situations:
a) inoperable cases and metastatic or recurrent tumors in
which the size and accessibility to surgical biopsy pre-
sents a problem; b) cases in which preoperative irradia-
tion or presurgical therapy is the initial treatment option;
and c) advanced tumors in which serial hormone recep-
tor studies may provide information regarding response
to therapy.
The assessment of hormone receptors on cytologic
material has been performed by immunocytochemistry
with good correlation with histologic and biochemistry
determinations. Some years ago, we described a method
of immunocytochemical assessment of estrogen receptor
status on alcohol-fixed smears obtained by FNA from
breast cancer patients, using a commercially available
monoclonal antibody with antigen retrieval, and the re-
sults were compared with the assessment by ER immu-
nocytochemical assay using the same procedure on forma-
lin-fixed tissue and with assessment by ER-ICA assay on
frozen sections. The results were scored semiquantitatively
using a five grade scoring system. Although we have been
critical in the use of score system in cytologic specimens,
especially in relation to the extension ofimmunoreactiv-
ity, we found a good correlation between the results ob-
tained on the cytologic specimens and on the histologic
material. The heterogeneity of ER expression within the
tumor should be taken in consideration whenever using
FNA material for semi-quantification of ER because it
might cause discrepant results. The putative usefulness of
quantification in cytochemical hormone receptor assays
remains controversial, and no consensus about the use of
semiquantitative scoring system or mere division of tumors
into positive and negative ones has been attained so far.
Although it has not been shown that quantitative values
beyond a defined level are helpful in selecting treatment
options, some authors using FNA material showed bet-
ter response to treatment with tamoxifen in patients with
more than 50% ER-positive tumor cells.
HER2/neu Assessment
The proto-oncogene c-erbB2 is localized on chromo-
some 17 and encodes a 185-kD transmembrane glycopro-
tein with tyrosine kinase activity, which possesses a close
sequence homology with the epidermal growth factor re-
ceptor. This oncogene is overexpressed in about one third
of breast cancers and its overexpression is associated with
Acta clin Croat 2002; 41:135-186 Conference papers
152 Acta clin Croat, Vol. 41, No. 2, 2002
high histologic grade, reduced survival, lower responsive-
ness to methotrexate-based treatment regimens and hor-
mone receptor modulators such as tamoxifen, as well as
higher responsiveness to doxorubicin-based regimens.
Recently, a humanized antibody against HER2/neu was
developed (Herceptin - Genentech, Inc, South San Fran-
cisco, CA), and might be used as a novel neoadjuvant pri-
mary therapy for HER2/neu positive breast cancer pa-
tients. Some authors showed that it is possible to deter-
mine the immunocytochemical expression of HER2/neu
in previously Papanicolaou-stained aspirates of breast car-
cinomas. They found a strong correlation between HER2/
neu immunocytochemistry of aspirates and their corre-
sponding tissue biopsies. In fact, the determination of
HER2/neu in smears and cytoblock preparations may be
as sensitive as, or even more sensitive than that of forma-
lin-fixed, paraffin-embedded tissue. In cytology, the pat-
tern of expression of HER2/neu is relatively uniform and
is evidenced by membrane staining. NCL-CB11, a mono-
clonal antibody against the internal domain of the HER2/
neu protein, gave better results in cell smears with stron-
gest reaction and least background staining.
The clinical use of Herceptin requires the evaluation of
HER2/neu amplification from every potentially eligible
patient. Fluorescence in situ hybridization (FISH) is cur-
rently regarded by the FDA as the gold standard method
for detecting HER-2/neu amplification. A big deal of dis-
cussion has emerged recently concerning the accordance
between the immunohistochemical assessment of HER2/
neu overexpression and the real amplification of the gene
assessed by FISH. For tissue sections, the semiquantitative
immunohistochemical approach accepted by FDA is de-
fined as positive membranous staining in more than 10%
of the neoplastic cells. Partial or incomplete, weak to mod-
erate, and moderate to strong membranous staining in more
than 10% of the tumor cells must be scored as 1+ (negative),
2+ (weak positive), and 3+ (strong positive), respectively.
Several reports showed a good correlation between a 3+
immunoexpression of HER2/neu and the amplification of
the gene using formalin-fixed paraffin embedded tissue;
however, in 1+ and 2+ cases, there is no correlation between
these parameters and these patients may have benefits as-
sessing c-erb-B2 amplification by FISH analysis. In the last
years, some authors have successfully assessed the amplifi-
cation of HER2/neu by FISH analysis in archival cytologic
fine needle aspirates and showed a good concordance with
paraffin-embedded tissue.
The findings reported so far support that FNA cytologic
samples might constitute the most cost-effective and easi-
est way to assess the HER2/neu amplification and overex-
pression, however, further studies are required to character-
ize the method for semiquantitative analysis of its immu-
nocytochemical expression. Besides, FISH analysis
requires microscopes with special filters and complex im-
age analysis system to interpret the fluorescent signal. With
the aim to supervene this drawback, the chromogenic in situ
hybridization (CISH), a new modification of FISH, that
enables detection of HER-2/neu gene copies with conven-
tional peroxidase reaction in breast cancer specimens using
regular microscopes, has been tested with outstanding re-
sults. Further studies in this front are needed to verify the
applicability of this new method in FNA cytologic samples.
P53 Expression
P53 encodes a 53 kD nuclear phosphoprotein with tu-
mor suppressor activity. The wild type P53 protein, which
is a transcription regulator, is present in the nuclei of all
mammalian cells where it appears to be involved in the
regulation of cell proliferation and apoptosis. Recent clini-
cal evidence supports a critical role of P53 status in provid-
ing prognostic information, mainly in node-negative breast
cancer patients. In fact, there is increasing evidence that
tumors lacking normal P53 function are clinically more
aggressive as they acquire a selective growth advantage be-
coming more resistant to ionizing radiation and some anti-
cancer drugs. P53 immunostaining is nuclear and could be
determined in previously Papanicolaou-stained aspirates of
breast carcinomas. When we compare P53 gene mutations
versus overexpression, the data obtained by molecular biol-
ogy methods for assessment of mutations give better prog-
nostic information than immunohistochemistry performed
with PAb 1801 monoclonal antibody. In histologic mate-
rial using a semi-quantitative approach we found an asso-
ciation between the presence of mutation in SSCP analy-
sis and strong P53 staining and absence of mutation in cases
with scarce and weakly positive neoplastic cells, however, we
do not test this system in FNA smears. Since it is possible
to detect P53 mutations and deletion in FNA material us-
ing polymerase chain reaction single strand conformation
polymorphism (PCR-SSCP) and DNA sequencing analy-
ses in DNA extracted from cell suspensions or archived
stained smears and that specific mutations in the P53 gene
are associated to primary resistance to chemotherapy, the
assessment of P53 mutations on FNA material could be
very useful to predict clinical behavior and responsiveness
to therapy in breast cancer. This is of particular value in a
Acta clin Croat 2002; 41:135-186 Conference papers
Acta clin Croat, Vol. 41, No. 2, 2002 153
primary chemotherapy setting, as complete tumor regres-
sion may occur and FNA-based pre-chemotherapy infor-
mation may represent the only available information unaf-
fected by therapy. The application of molecular biology
techniques to the existing archival smears may become a
valuable tool to detect genetic changes in samples from
breast cancer aspirates, making FNA a reliable and helpful
tool for the diagnosis, prognostic assessment and therapeu-
tic management of breast cancer patients.
Sialyl-Tn Expression
Sialyl-Tn (STn) is a core region carbohydrate antigen
formed by the premature 2-6 sialylation of N-acety-
lgalactosamine whose expression is associated with some
human malignancies. In fact, neoplastic transformation is
almost invariably associated with marked changes in cell
membrane glycoconjugates due to abnormal expression or
depression of DNA encoding glycosyl transferases and the
expression of simple mucin-type antigens, including STn
is highly restricted in normal adult tissues. In our experi-
ence, the expression of this marker in breast cancer is asso-
ciated with the presence of axillary metastases, lack of hor-
monal receptor, and high histologic grade. Moreover, some
authors have demonstrated that STn positivity appears to
be a marker of resistance to adjuvant chemotherapy. Using
immunocytochemistry, we documented STn expression in
mammographically detected breast lesions diagnosed by
FNA cytology. Therefore, the determination of expression
of STn in breast aspirates could be a useful marker to as-
sess resistance to chemotherapy as well as to identify cases
with high risk of axillary metastases.
Assessment of Telomerase Activity
Telomeres are repetitive sequences at the ends of chro-
mosomes that protect chromosomes from incomplete rep-
lication, nuclease degradation, and end-to-end fusion dur-
ing replication, playing a major role during DNA replica-
tion. In most somatic cells, after each cell division, the te-
lomeres are eroded, leading to a progressive shortening of
their length. When one telomere reaches the critical point,
the cell stops dividing, and senesces. The maintenance of
telomeres depends on the telomerase activity. Telomerase
is a ribonucleoprotein complex responsible for de novo te-
lomere synthesis and addition of telomeric repeats to exist-
ing telomeres. Telomerase activity (TA) is almost restricted
to embryonic cells, germ cells, and malignant neoplastic
cells; very low levels of this enzyme have been detected in
somatic tissues, mainly restricted to the basal cell layer
ofseveral epithelia and cells in the terminal ducts of the
breast. Telomerase activity can be measured in vitro by us-
ing the telomeric repeat amplification protocol (TRAP), in-
cluding cells obtained by FNA specimens. The presence of
TA was demonstrated in 80% to 90% of breast carcinoma
FNA samples; however, some benign lesions presented
some level of telomerase activity, including fibroadenomas.
Further evaluation of the sensitivity and specificity of TA
for malignant cells is required before this technique could
be accepted as a new marker in routine cytology.
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MAMMARY NEOPLASIA IN CAST AND DOGS
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Mammary neoplasms are very prevalent in dogs and
cats, but are rare in other domesticated species. Because of
their prevalence in these companion animals, and because
they are a model for human breast cancer, they are deeply
investigated clinically, histologically, immunohistochemi-
cally and with other molecular pathology techniques. Mam-
mary neoplasms are the third most frequently occurring
tumor in female cats, following hematopoietic neoplasms
and skin tumors. The incidence of mammary tumors in this
species is less than half that of humans and dogs, neverthe-
less, these tumors account for 17% of neoplasms in female
cats. The great majority (about 80%) of feline mammary
tumors are malignant (adenocarcinomas). Breed predispo-
sition (Siamese) has been speculated but not proven. Mam-
mary tumors occur primarily in intact cats from 9 months
to 23 years of age, with a mean age of 10 to 12 years. Sev-
eral reports have documented an association between the
prior use of progesterone-like molecules and the develop-
ment of benign or malignant feline mammary neoplasms.
While low concentrations of progesterone receptors have
been found in the cytoplasm of some feline mammary tu-
mors, dihydrotestosterone receptors have not been identi-
fied. Only 10% of the feline tumors examined were posi-
tive for estrogen receptors: a much higher percentage of
estrogen receptor positive tumors are seen in dogs and hu-
mans. Tubular, papillary, and solid adenocarcinomas are the
most common malignant tumors and the majority present
a combination of tissue types in each tumor. Sarcomas,
mucinous carcinomas, duct papillomas, adenosquamous
carcinomas, and adenomas are rarely seen. Mammary gland
dysplasia, while infrequent, needs to be differentiated from
malignant neoplasms. Lobular hyperplasia and fibroepi-
thelial hyperplasia are types of non-inflammatory hyperpla-
sia identified in the mammary gland of the cat. These hy-
perplastic conditions are relatively common, and thought
to be associated with hormonal stimulation of the glandu-
lar tissue, which decreases following ovariohysterectomy.
Benign tumors include simple and complex adenomas, low-
and high-cellularity fibroadenomas, benign mixed tumors
and duct papillomas. Feline mammary gland neoplasm can
involve any or all of the glands and is distributed equally
between the left and right sides. Multiple gland involvement
occurs in more than half of affected cats. Metastatic lung
and thorax involvement may be extensive. Tumor size is the
single most important prognostic factor for malignant fe-
line mammary tumors. Other significant prognostic factors
affecting recurrence in and survival of feline malignant
mammary tumors are the extent of surgery and histologic
grading of the tumor. Cats with a tumor size of greater than
3 cm in diameter will have a median survival time of 4 to 6
months. Cats with a tumor size of 2 to 3 cm in diameter
will have a significantly increased survival time with a me-
dian of about 2 years. Cats with tumor less than 2 cm in
diameter have a median survival time of more than 3 years.
Thus, early diagnosis and treatment is a very important
prognostic factor for malignant feline mammary tumors.
Mammary tumors are extremely common in intact female
dogs, and account for at least 50% of all reported neoplasms.
At least 70% of intact bitches will develop a clinically de-
tectable mammary tumor if they live to 15 years of age, and
almost all of them will have microscopic tumor foci. Ova-
riohysterectomy prior to the first heat cycle greatly reduces
the risk (more than 80%) of developing mammary neopla-
sia later in life, with the benefits reduced with time and no
benefits of spaying after the second heat. Some report that
50% of canine mammary tumors aremalignant and 50% of
the malignant neoplasms metastasize, others reports that
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metastasis is much less frequent. The most reliable predic-
tor of true behavioral malignancy in canine mammary tu-
mors is local invasion. While local invasion is readily de-
tected by histologic examination of the excised tumors, it
can also be predicted with accuracy by clinical examination.
Tumors that seem to be fixed to the underlying tissue, cross
the midline, or are otherwise obviously infiltrative are likely
to be true malignancies. A bitch with one detected mam-
mary tumor very often will have numerous microscopic foci
in the same or other glands. Malignant tumors of the dog
include several types of carcinomas: noninfiltrating (in situ),
complex, simple, tubulopapillary, solid, anaplastic and some
special types of carcinomas including spindle, squamous,
mucinous, and lipid rich carcinomas. Sarcomas, which are
much less frequent, include fibrosarcomas, osteosarcomas,
and other sarcomas. In addition, carcinosarcoma and car-
cinoma or sarcoma within a benign neoplasm have been
described. Benign tumors include simple, complex, basaloid
adenomas, fibroadenomas, benign mixed tumors, duct pap-
illomas. Other described changes in the canine mammary
gland include ductal, lobular, and epithelial hyperplasia,
adenosis, cysts, duct ectasia, fibrosclerosis and gynecomas-
tia.
DIAGNOSTIC IMAGING FOR THE
IDENTIFICATION OF CARDIAC TUMORS
IN HUMANS AND DOGS
C. M. Bussadori* S. Biasi** C. Quintavalla*** D.
Pradelli*** L. Marconato****
*Clinica Veterinaria G.Sasso, Milan, Italy **Unit&#224;
Operativa di Cardiologia Clinica S.Carlo, Paderno
Dugnano, Milan, Italy ***Istituto di Clinica Medica
Facolta’ di Medicina Veterinaria, Università di Parma
****School of Veterinary Medicine, Department of
Pathobiology, University of Pennsylvania, USA
Diagnostic imaging (particularly echocardiography
and MRI) has increased the frequency of identification of
cardiac tumors. Although still uncommon, cardiac neopla-
sia is more than an academic curiosity. In human patients,
benign tumors are more frequent than malignant, with
myxomas being most prevalent. A sex predisposition has
been observed, with a higher prevalence in females. Car-
diac tumors are diagnosed in patients of all ages. The most
frequent cardiac tumors in dogs are hemangiosarcomas,
chemodectomas, ectopic thyroid carcinomas, and pericar-
dial mesothelioma. For most of these tumor types there
is a demonstrated breed predisposition; for example
chemodectomas are most commonly found in brachio-
cephalic breeds. Diagnostic imaging is needed to guide
surgical treatment: surgical removal of these tumors has
grown following the introduction of echocardiographic
examination. Diagnostic imaging is useful even in prena-
tal diagnosis of cardiac neoplasias such as rhabdomyoma
and rhabdomyosarcoma. Almost all cardiac related tumors
could be identified by echocardiography, particularly int-
racardiac ones. When transthoracic echocardiography is
unable to fully evaluate the edges of cardiac masses,
transesophageal echocardiography can be used to provide
more complete diagnostic information. MRI synchronized
with cardiac cycle can achieve additional information.
Echocardiography and MRI are complementary diagnos-
tic tools. In the dog, cardiac tumors are commonly typi-
fied by echocardiography based on their peculiar morpho-
logical features. Even in human patients, echocardio-
graphy and MRI give enough information to identify the
type of cardiac tumor.
DRUG-INDUCED LIVER DISEASES
H. Denk
Department of Pathology, University of Graz, Graz,
Austria
The liver is the central organ of drug metabolism and
also a major target of drug toxicity. Many drugs and
chemicals are potentially hepatotoxic, including drugs
used for treatment of liver diseases. It is known from sev-
eral studies that about 2% to 10%, in older age groups even
more, of hospitalized icteric patients are drug victims and
about 25% of acute necrotizing liver diseases are related
to drug intake. Moreover, drugs are also causes of chronic
liver diseases. Practically all types of acute and chronic liver
disorders can be drug-induced. Therefore, diagnosis de-
pends on close cooperation between the pathologist and
clinician, and particularly on the information about the
patient. The diagnosis of adverse drug effects is important
since further administration of a drug potentiates liver
injury and may even lead to a chronic course.
Hepatotoxic drugs can be divided into intrinsic and
idiosyncratic types. Intrinsic hepatotoxins mostly have
cytotoxic and less often cholestatic effects, which are dose-
dependent, fairly well predictable with a short latent pe-
riod. The lesions are reproducible in animal experiments.
Liver disease due to this type of drugs is rather rare and
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mostly associated with overdose. A typical example is ac-
etaminophen (paracetamol) intoxication.
Liver injury caused by idiosyncratic liver toxins is more
often seen. Only a small percentage of susceptible patients
are affected. These drug effects are unpredictable and usu-
ally not experimentally reproducible. The latent period
between the drug administration and onset of liver disease
is often long and variable, but shorter latent periods are
seen upon readministration. The idiosyncratic type of
drug-induced liver injury is either caused by an immune
response against the drug or a metabolite in association
with cellular proteins, or by genetically determined varia-
tions in drug metabolism and resulting toxic metabolites.
The morphologically detectable consequences of ad-
verse drug reactions are variable and in principle nonspe-
cific, although eosinophilia, pigment-containing mac-
rophages, steatosis, and ductular reaction are suggestive of
drug etiology. Morphologic alterations comprise adaptive
responses of hepatocytes, hepatitic and non-hepatitic le-
sions, granuloma formation, cholestasis, finally fibrosis or
even cirrhosis, and vascular and neoplastic changes.
Cellular adaptation with increased amounts of smooth
endoplasmic reticulum is morphologically characterized
by ground glass-like appearance of hepatocytes, predomi-
nantly in centrilobular areas.
The most frequent manifestations of intrinsic hepato-
toxins are steatosis (macro- or microvesicular) and necro-
sis, usually in acinar zone 3. Macrovesicular steatosis for
example may result from the administration of corticoster-
oids, the microvesicular form may be caused e.g. by tetra-
cyclins, anticonvulsants or anti-inflammatory drugs. Micro-
vesicular steatosis often results from the inhibition of mi-
tochondrial β-oxidation. Parenchymal necrosis may be
zonal (perivenous, periportal, intermediate), non-zonal or
massive. Intrinsic hepatotoxins tend to the induction of
zonal, idiosyncratic or non-zonal necroses. Typically, peri-
venous zonal necrosis is caused by an overdose of para-
cetamol.
Acute hepatitis may follow the administration of di-
verse drugs, including anesthetics but also herbal prepa-
rations. It resembles an idiosyncratic reaction with latent
periods between exposure and manifestation of liver dis-
ease varying between days and months. The morphology
is similar or even identical to acute viral hepatitis with
variable degrees of necrosis, steatosis, cholestasis, lobular
activity and portal inflammation. The presence of epithe-
lioid cell granulomas suggests drug etiology. A classical
example of this type of drug reaction is halothane hepati-
tis. In its early stage, centrilobular necrosis caused by toxic
metabolites prevails, whereas in the later stage the hepa-
titic picture predominates. This adverse reaction to hal-
othane occurs in about 1 to 10 of 30000 exposed individu-
als but the frequency increases to about 1 in 100 follow-
ing multiple exposures.
Multiple or prolonged exposures to certain drugs may
lead to chronic liver disease. Drug-induced chronic hepa-
titis is indistinguishable from chronic viral or autoimmune
hepatitis both with respect to morphology and serology
(e.g., occurrence of autoantibodies). Drug-induced chronic
hepatitis is often accompanied by pronounced lobular ne-
crosis, lymphocytic, plasmacytic and eosinophil-granulo-
cytic inflammation in variable combinations. Chronic hepa-
titis may be induced by acetaminophen (paracetamol),
tetracyclins, sulfonamides, anti-inflammatory, anticonvul-
sive, antihypertensive and antiarrhythmic drugs.
Steatohepatitis, characterized by steatosis, hepatocel-
lular ballooning, Mallory body formation, inflammation
and pericellular fibrosis, morphologically resembling al-
coholic hepatitis, can be caused by a variety of drugs, in-
cluding synthetic estrogens, amiodarone, methotrexate
and tamoxifen. The risk of development of steatohepatitis
is enhanced by obesity.
Cholestasis is a common manifestation of drug-in-
duced liver disease. It may be classified as canalicular,
hepatocanalicular or ductular. Pure canalicular cholestasis
without morphologic signs of liver cell damage and in-
flammation occurs in a small percentage of genetically
susceptible individuals after administration of 17-α-alky-
lated anabolic or contraceptive steroids. Jaundice usually
develops 1-6 months after commencement of treatment.
In contraceptive pills, the estrogen component is the ma-
jor mediator of cholestasis. Hepatocanalicular cholestasis
develops, e.g., in 1%-2% of patients treated with chlorpro-
mazine and is associated with portal and lobular inflam-
mation of varying degrees, enlargement of hepatocytes,
multinucleation and mitoses. The lesion may vary from
almost pure cholestasis to pronounced hepatitis.
Chronic drug-induced cholestatic conditions are oc-
casionally observed and may be accompanied by bile duct
lesions finally leading to a vanishing bile duct syndrome.
About 30% of granulomas in the liver are drug-in-
duced. Hepatic granulomas should, therefore, always rise
suspicion of an adverse drug reaction. Many drugs can be
incriminated, with non-steroidal anti-inflammatory drugs
playing a major role in this respect.
The vascular system of the liver may also be the tar-
get of adverse drug reactions (anabolic and contraceptive
steroids, cytostatic drugs, herbal preparations), which in-
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clude sinusoidal dilatation (anabolics, contraceptives) and
endothelial lesions with resulting veno-occlusion disease
(cytostatic drugs).
The association of hepatocellular adenomas with long-
term administration of contraceptives and anabolics is a
well known although a rather rare event. The risk associ-
ated with contraceptives increases with prolonged intake,
higher estrogen content and in individuals of older (above
30 years) age groups.
In conclusion, drug-induced lesions of the liver show
a variable morphology on liver biopsy. The diagnosis is
important since discontinuation usually results in recov-
ery. Drug-induced liver injury should always be consid-
ered in patients with hepatobiliary symptoms, particularly
in older age groups and in females who are more suscep-
tible. Close cooperation between the pathologist and cli-
nician is an imperative to establish a correct diagnosis.
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THE ONE MEDICINE CONCEPT:
APPLICATIONS IN VETERINARY AND
HUMAN CLINICAL TOXICOLOGY
R. H. Poppenga
American Board of Veterinary Toxicology
Diagnostic Toxicology Laboratory, School of Veterinary
Medicine, University of Pennsylvania, Philadelphia, USA
The School of Veterinary Medicine at the University
of Pennsylvania was founded in 1884. The aims of the
School, as stated in the Announcement of its formation,
were “to give instruction, both theoretical and practical,
in all branches pertaining to the scientific study of the
elements of medicine, and the practical application of
these elements to the domestic animals, in the preserva-
tion of their health, in their employment as useful aids to
man, and in the diseases to which they are subject.” Thus,
from the outset, the School was identified as a branch of
medicine. Of note, ten of the School’s original faculty had
M.D. degrees. The philosophy of there being only “one
medicine”, involving both humans and animals, has guided
the school over the last 117 years. Veterinary medicine has
certainly benefited from advances in human medicine in
a number of specialty areas, including veterinary clinical
toxicology. Conversely, veterinary medicine has improved
the health and well-being of people in many significant
ways. More specifically, veterinarians and veterinary toxi-
cologists have contributed to the advancement of the spe-
cialty of human clinical toxicology by 1) improving the
diagnosis and treatment of human and animal toxicant-
induced disease, 2) improving our understanding of toxi-
cologic mechanisms and comparative toxicology and pa-
thology, 3) enhancing the recognition of new and emerg-
ing toxicologic threats, and 4) preventing human and ani-
mal toxicant-induced disease. Veterinary toxicologists and
analytical chemists have been at the forefront in the uti-
lization of a variety of analytical techniques for the detec-
tion of toxicants in a number of biological and environ-
mental matrices. The day-to-day use of inductively cou-
pled plasma argon emission spectroscopy (ICPAES) for
the diagnosis of metal intoxications was first instituted in
veterinary diagnostic toxicology laboratories. Adaptation
of sophisticated analytical techniques for broad-based
toxicant screening continues with the use of liquid chro-
matography ∑ mass spectroscopy and ICP-mass spectros-
copy systems. Veterinarians were early investigators of the
safety and efficacy of fomepizole (4-methylpyrazole) for
the treatment of ethylene glycol intoxication of dogs. From
a comparative toxicology standpoint, recent investigations
in cats have demonstrated species differences with regard
to the effectiveness of fomepizole to inhibit alcohol de-
hydrogenase. The impact on human health of persistent
organic pollutants such as PCBs has been difficult to as-
sess. Investigation of seal mortalities in the Baltic has dem-
onstrated that ingestion of PCB-contaminated fish can
impair immune function and potentially exacerbate infec-
tious disease outbreaks. Such studies have direct applica-
tion to the potential risks to humans of eating PCB-con-
taminated foodstuffs. Aflatoxins were first isolated from
peanut meal during investigations of an epizootic of “tur-
key X” disease in England; histopathologic examination
of affected turkeys demonstrated the hepatotoxicity of
these mycotoxins. Subsequent studies revealed their ani-
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mal and human carcinogenic potential. Veterinary toxi-
cologists were the first to isolate and chemically charac-
terize the fumonisin mycotoxins, common contaminants
of corn and the cause of several animal diseases including
equine leucoencephalomalacia (ELEM). Isolation and
chemical characterization of these mycotoxins has led to
considerable investigation into their mechanism(s) of toxic
action and their potential impact on human health. Vet-
erinary toxicologists play an essential role in preventing
toxicant-induced human disease. They are involved in
assuring that feedstuffs intended for livestock consump-
tion are free of chemical contaminants that might result
in violative residues in meat, milk and eggs destined for
human consumption. Investigation into unexplained food-
animal deaths by veterinary toxicologists often prevents
chemically-contaminated animal products from being
used as human food. Veterinary toxicologists play an es-
sential role in the use of animals as biomonitors of envi-
ronmental quality. The diagnosis of lead exposure and/or
intoxication in a household is often initially made in a pet
such as a dog or cat. Such a diagnosis can prevent signifi-
cant exposure of young children to lead or early recogni-
tion of an adverse effect. In the U.S., the establishment
of the National Animal Poison Control Center (NAPCC)
nearly 15 years ago has provided a valuable database of
animal exposures to toxicants. The NAPCC database as-
sists in the recognition of potential toxicant hazards to
humans. For example, information on the intoxication of
animals by some human dietary supplements has been
useful in characterizing their potential hazard to people.
Additional animal poison information services are now
available in England and France. In summary, veterinary
clinical toxicologists interface directly with their human
colleagues in a variety of ways. It is important that human
and veterinary clinical toxicologists recognize that there
is only “one clinical toxicology” and seek ways to promote
and exploit such a concept for the mutual benefit of our
human and animal patients.
DIAGNOSIS OF SOLITARY
CYSTS OF MAMMAE
N. V. Bogomolova, M. A. Mikhel, N. A. Bigeldina
Saratov State Medical University, Saratov, Russia
The diagnosis of mammary cysts in women does not
pose major difficulties for most physicians experienced in
the treatment of the given pathology. Nevertheless, the se-
quence of diagnostic measures and interpretation of their
outcomes are not always optimum either from the point of
reliable verification of the diagnosis, or of diagnostic com-
pleteness of this condition. Interesting experience in the
diagnosis of mammary cysts has been collected at the
Saratov regional center of family planning and reproduc-
tion. A series of 107 cases of mammary cysts appearing as
solitary cysts were found to be multiple, monolateral or bi-
lateral cysts. It is necessary to note that the efficiency of
clinical diagnosis of cysts largely depends on their perfor-
mance ∑ depth, degree of filling, and possible imitation of
fatty involution of mammae. Taking it into account, in case
of solitary cyst revealed by clinical examination, diagnostic
ultrasonography before traditionally used pneumo-
cystography is helpful. Considering high (98%) specificity
of the examination for the diagnosis of cysts, similar tac-
tics does not only allow for detection of nonpalpable cysts,
but also evaluation of their size and localization. For pre-
cise topologic picture of the cyst localization, single biopsy
with consequent pneumocystography can be used. In this
way, the radiation is considerably reduced as compared with
radiography. Moreover, this approach need not be limited
exclusively by ultrasonography finding, as pneumocy-
stography allows for more concrete investigation of the in-
ternal wall for availability of cysts and choice of subsequent
treatment.
FINE NEEDLE ASPIRATION CYTOLOGY
OF ADENOID CYSTIC CARCINOMA OF
THE BREAST. REPORT OF THREE
CASES WITH THIN-PREP AND
IMMUNOCYTOCHEMICAL STUDIES
E. Garcia Ureta, A. Veiga Barreiro
Hospital Juan Canalejo As Xubias, Spain
Adenoid cystic carcinoma (ACC) of the breast is a rare
neoplasm, yet its diagnosis is important because it has an
excellent prognosis compared to most other malignancies
of the breast. In this communication, our experience with
three cases of AAC of the breast is presented in which the
diagnosis was based on fine-needle apiration cytology
(FNAC). In three female patients aged 78, 60 and 49,
FNAC was perfomed according to standard procedure
using a 23-gauge needle. Two slides were stained with
Papanicolaou and another two slides with May-Grün-
wald-Giemsa. Additional slides were stained with alcian
blue and PAS (before and after diastase digestion). In two
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cases, the needle was rinsed in Preserv CyT solution af-
ter each pass and the material obtained from the rinse was
used for Thin-Prep technique, along with the material
obtained from a new FNAC. Immunocytochemistry was
performed using standard methods. The antibodies used
included keratin, epithelial membrane antigen, vimentin,
S-100 protein, smooth muscle actin, laminin and type IV
collagen. Cytologic findings were typical for cribriform
ACC in each case. The May-Grünwald-Giemsa and
Papanicolaou stained slides showed three-dimensional
clusters of uniform cells with cystic spaces. The nuclei were
round and uniform, small and ovoid, with fine chromatin
and scanty cytoplasm arranged arond cores or spheres of
homogeneous acellular material. The cystic spaces con-
tained cyanophilic amorphous material that stained posi-
tive for PAS an alcian blue stains. Thin-Prep slides con-
tained less cells. It showed good correlation with conven-
tional preparation. Cytomorphology in Thin-Prep slides
allowed a definitive diagnosis. Immunocytochemical stud-
ies demonstrated positive staining of epithelial cells with
low-molecular-weight cytokeratin. Antibodies to S-100
protein and smooth muscle actin demonstrated positive
staining of other cells within papillary groupings consis-
tent with myoepithelial cells. Studies for type IV collagen
and laminin showed intense staining of the spherules. The
aspirate yielded a typical smear composed of round, mul-
tilayered clusters of uniform cells arranged around cores
of homogeneous, acellular material, strongly suggestive of
the diagnosis of ACC. The cytologic differential diagno-
sis includes adenosis tumor, collagenous spherulosis, pleo-
morphic adenomas, adenomyoepithelioma and pseudo-
adenoid cystic carcinoma. To our knowledge, the ACC
cases reported here are the first examples of this type of
breast cancer assayed by Thin-Prep technique.
PRIMARY MALT LYMPHOMA OF THE BREAST.
A CASE WITH CYTOLOGIC AND
IMMUNOCYTOCHEMICAL DIAGNOSIS
E. Garcia Ureta, A. Veiga Barreiro, J. M. Mosquera
Reboredo, G. Matheu Capó
Hospital Juan Canalejo As Xubias, Spain
Primary lymphoma of the breast is rarely considered
in differential diagnosis of a breast mass. The incidence
in different studies varies from 0.076% to 0.53% of ma-
lignant lesions of the breast. It accounts for 10% of all
breast sarcomas, 2.2% of all extranodal non-Hodgkin’s
lymphomas, and 0.38% of all non-Hodgkin’s lymphomas.
Low-grade lymphomas of the breast, particularly mucosa-
associated lymphoid tissue (MALT) lymphomas, have
been exceedingly rare. In this report, we present cytologic
features of a patient with breast MALT lymphoma. An
81-year-old woman presented with a 2-month history of
a right breast mass detected by mammography, not asso-
ciated with pain or any other symptoms. There was no
other remarkable medical history. Fine-needle aspiration
(FNA) biopsy of the breast was performed. A total of six
Papanicolaou and May-Grünwald-Giemsa stained slides
were prepared. Additional material was used for immu-
nocytochemical studies with CD20 and CD3 primary
antibodies. Cytologic features: the smears showed a rela-
tively uniform population of lymphoid cells. Scattered
large, thick clusters of epimyoepithelial cells with inti-
mately associated lymphocyte tangles were also present.
Normal mammary gland acini were absent. The lympho-
cytes were composed of predominantly small-sized cells
with round to irregular nuclear outlines, the chromatin was
coarse and with small nucleoli, the cytoplasm was scant
and basophilic. Immunocytochemical studies revealed that
lymphoid cells were B-cells (CD20 +). Histology, immu-
nohistochemical and gene rearrangement studies con-
firmed the cytologic diagnosis. The material obtained
from our patient had a distinctive cytologic morphology.
Monoclonality was demonstrated by immunocytoche-
mistry. Differential diagnosis of FNA biopsy material from
mammary gland lesions includes reactive lymphoid tissue.
To our knowledge, this is the first description of a low-
grade MALT lymphoma in a mammary gland to be di-
agnosed by FNA.
FINE NEEDLE ASPIRATION CYTOLOGY
OF MAMMARY PSEUDOANGIOMATOUS
STROMAL HYPERPLASIA:
REPORT OF THREE CASES
E. Garcia Ureta, A. Veiga Barreiro, J. M. Mosquera
Reboredo, G. Matheu Capó
Hospital Juan Canalejo As Xubias, Spain
Pseudoangiomatous stromal hyperplasia (PASH) was
first described by Vuitch et al. in 1986 as a benign lesion
composed of stromal tissue proliferation with a complex
pattern of interconnected spaces. Clinical features of
PASH consist of a palpable, mobile, firm painless mass.
This report describes fine needle aspiration cytology
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(FNAC) features of three cases of mammary PASH that
presented as palpable masses. In three female patients aged
40, 37 and 39, the lesion presented as a discrete, painless,
unilateral breast mass. The three cases were clinically and
mammographically diagnosed as fibroadenoma. In these
patients FNAC was performed using 23 to 25 gauge
needles. All subsequently obtained surgical specimens
were routinely processed and stained with Papanicolaou
and May-Grünwald-Giemsa.The three patients’ samples
showed a similar aspect. The aspirates were cellular show-
ing large fragments of monolayered two-dimensional duc-
tal epithelium. There were clusters of cohesive ductal cells
dispersed throughout the smears. Scattered groups of
poorly cellular stromal fragments and a background with
bipolar, naked nuclei were also identified. Grossly, the
tumors were well circumscribed, with a smooth external
surface and a variable consistency from firm to rubbery.
Microscopically, the tumors were composed of intermixed
stromal and epithelial elements. The histologic features
were identical to those of classical cases of PASH. In all
cases, the most striking histologic finding was a complex
pattern of anastomosing empty spaces in the collagenized
hypocellular stroma. Although the benign nature of PASH
can generally be recognized on FNAC material, the cy-
tologic features are not specific, and its distinction from
fibroadenoma and fibrocystic changes is not possible. In
addition, it is crucial to correlate the clinical characteris-
tics, mammographic studies and cytologic findings in or-
der to avoid a diagnosis of malignancy.
FINE NEEDLE ASPIRATION CYTOLOGY OF
MAMMARY ADENOMYOEPITHELIOMA.
A CASE REPORT
E. Garcia Ureta, A. Veiga Barreiro, G. Matheu Capó,
J. M. Mosquera Reboredo
Hospital Juan Canalejo As Xubias, Spain
Adenomyoepithelioma is a rare breast lesion, which
was first described by Hamperl in 1970. Although the
histologic features of adenomyoepithelioma have been
well described, there are few literature reports document-
ing the cytology of these lesions. The purpose of this com-
munication is to describe the FNA cytology features in a
case of adenomyoepithelioma. A-57-year old female pre-
sented with a hump in the upper outer quadrant of the
right breast. No other symptoms or signs were present.
Smears were prepared from fine needle aspirate of the
hump. Air-dried smears were stained with May-Grün-
wald-Giemsa and alcohol-fixed smears were stained with
Papanicolaou stain. The aspirates were cellular and con-
sisted of large tightly cohesive aggregates of cells along
with small amounts of stromal material. Stromal material
was randomly distributed throughout cellular aggregates.
On high power, two cell types were identified. One type
was predominantly basaloid, spindle-shaped with cyto-
plasm varying from clear to eosinophilic. The nuclei were
rounded with minute nucleoli. The second cell type was
columnar to cuboidal, having finely granular eosinophilic
to foamy cytoplasm, globoid nuclei and prominent
nucleoli. Numerous bare nuclei were present. Mitotic fig-
ures were absent. Histologic examination showed the clas-
sic features of adenomyoepithelioma. Adenomyoepithe-
lioma has a dual component of epithelial and myoepithe-
lial cells. The presence of myoepithelial cells is a helpful
finding in identifying some proliferative lesions of the
breast as benign. Benign and malignant lesions are ade-
nosis tumor, collagenous spherulosis, pleomorphic ad-
enoma and adenoid cystic carcinoma in which myoepithe-
lial cells are a prominent and diagnostically important
component. These lesions should be considered on differ-
ential diagnosis. More cases of myoepithelial cells in the
lesion of the breast have to be studied in order to under-
stand better their cytologic features.
FINE NEEDLE ASPIRATION CYTOLOGY OF
PLEOMORPHIC ADENOMA OF THE BREAST.
CASE REPORT
E. Garcia Ureta, A. Veiga Barreiro, J. M. Mosquera
Reboredo, G. Matheu Capó
Hospital Juan Canalejo As Xubias, Spain
Pleomorphic adenoma of the breast (PAB) is an uncom-
mon but known benign neoplasm that might be misinter-
preted both clinically and pathologically as a malignant
tumor. There are only sporadic case reports of these lesions
in the breast. We herein report the cytologic characteristics
of an additional PAB diagnosis by fine-needle aspiration
(FNA). An 80-year-old woman presented with a mass in
her left breast that had persisted for two months. No other
lesions were observed. The patient underwent ultrasound
guided FNA of the mass using a 22-gauge needle. Air-dried
smears were stained with May-Grünwald-Giemsa (MGG)
and alcohol-fixed smears were stained with Papanicolaou
stain. Cytologic examination of the aspirate revealed mod-
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erate cellularity with isolated cells or clusters of epithelial
cells. The smears showed both small dense clusters and large
loose, irregular clusters with fuzzy margins or a spindle cell
core. The lesion was composed of uniform, small cells with
round to oval nuclei with finely granular chromatin. Epi-
thelial cells contained abundant cytoplasm with distinct
cytoplasmic borders with a plasma cell-like appearance in
isolated cells. Fibrillary chondromyxoid ground substance
was observed. Mytotic figures were absent. The surgical
specimen showed a typical picture of pleomorphic adenoma.
Thus in the aspirate, a dual population of epithelial and
myoepithelial cells were identified in cell aggregates and nu-
merous bare nuclei were present. Cytologic differential di-
agnosis of pleomorphic adenoma is wide. The main cyto-
logic differential diagnoses include fibroadenoma and low
grade phyllodes tumor. Aspirates from these lesions may
contain large cellular aggregates with a dual population of
epithelial and myoepithelial cells, abundant bare nuclei and
stromal elements. Adenosis tumor, collagenous spherulosis,
adenomyoepithelioma and adenoid cystic carcinoma should
be considered on the differential diagnosis of breast aspi-
rates containing a dual population of cells.
ASSOCIATION BETWEEN HER2/NEU
EXPRESION AND HORMONE RECEPTOR
STATUS IN BREAST CANCER PATIENTS
Yashar G1, Basheska N1, Kraleva S2, Vasev N2, Ivkovski
Lj1, Prodanova I1, Kubelka K1, Smichova S2, Zografski G1
Department of Histopathology and Clinical Cytology1,
Institute of Radiotherapy and Oncology2, Skopje
Medical Faculty, Skopje, Republic of Macedonia
Determination of HER2/neu expression by immuno-
histochemistry is mandatory for application of Herceptin®
therapy in breast cancer patients. The purpose of this study
was to investigate the association between HER2/neu ex-
pression and hormone receptor status, as well as with other
clinicopathological parameters in breast cancer patients.
HER2/neu, p53 and Ki-67 expression was determined in
169 postoperative stage I-III (UICC, 1997) breast cancer
patients using the standardized DAKO HercepsTest® and
immunoperoxidase technique, respectively. The results of
HER2/neu immunoreactivity were evaluated by perform-
ing the standardized scoring system (0 = negative, 1+ =
weakly positive, 2+ = positive, 3+ = strongly positive stain-
ing), while ER and PgR were scored in a semiquantitative
fashion (ER-ICA and PR-ICA). The results from HER2/
neu expression were correlated to hormonal receptor status
and clinicopathological parameters (tumor size, histopatho-
logic grade, nuclear grade, histologic type of the tumor,
lymph node status and patient age). Statistical significance
was determined with χ2 and Fisher’s exact test. HER2/neu
expression was positive in 66 patients (37%). There was no
significant association between the values of HER2/neu and
ER/PgR status, or with any other clinicopathological pa-
rameter. ER status significantly correlated with PgR status
(p<0.01), tumor size (p<0.01), lymph-node involvement
(p<0.01) and tumor type (p<0.01). PgR status was related
to the histopathologic grade (p<0.01), lymph-node status
(p<0.01), tumor type (p<0.01) and patient age (p<0.01).
HER2/neu is a relatively new promising marker in predict-
ing the response to target specific therapy. However, its pre-
dictive value remains a complex and inconclusive subject.
According to our results, the prognostic potential of HER2/
neu seems to be independent from hormone receptor sta-
tus and any other clinicopathological parameter in breast
cancer patients.
IMMUNOHISTOCHEMISTRY
OF MALE BREAST CANCER
D. Tomas, H. Jurlina, M. GlasnoviÊ, T. LeniËek, M.
Elez, V. GladiÊ, B. Kruπlin
Ljudevit Jurak University Department of Pathology,
Sestre milosrdnice University Hospital, Zagreb, Croatia
Although common in females, breast cancer is very
rare in males. It accounts for less than 1% of all cancer
cases in males and less than 1% of all breast cancer cases.
Due to its rarity there is very little information available
regarding male breast cancer. The objective of this study
was to shed some light on male breast cancer statistics by
using breast cancer cases found in the cancer cases regis-
try of the Sestre milosrdnice University Hospital and com-
paring them to other similar studies. Data were collected
in 21 (0.88%) male patients, out of a total of 2380 male
and female patients in whom breast cancer was diagnosed
as the result of biopsies performed at the Ljudevit Jurak
University Department of Pathology during the 1980-
2001 period (22 years). Special attention was paid to the
last six cases of male breast cancer found in the 1995-2001
period. Formalin fixed and paraffin embedded tumor tis-
sues were cut into 5-mm sections, deparaffinized and
stained with hematoxylin and eosin. Immunohistochem-
istry for estrogen, progesterone, prostate specific antigen
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(PSA) and HER-2/neu was also performed. The mean age
in 21 male patients with breast cancer at the time of di-
agnosis was 62.4 years, which is consistent with other
clinical studies of male breast cancer. The mean percent-
age of male breast cancer cases was 0.88%, which is in
agreement with <1% of male breast cancer cases reported
in other studies. Nineteen of 21 (90.4%) male breast can-
cer cases were infiltrating ductal (NOS: no other speci-
fied), one (4.8%) was intraductal, and one (4.8%) medul-
lary cancer. Special attention was paid to all biopsies per-
formed in males with breast cancer during the 1995-2001
period. These six were tested for estrogen and progester-
one receptors as well as for the presence of PSA and HER-
2/neu (c-erbB-2) markers. Five (83.3%) of these six pa-
tients were positive for estrogen receptors, and six (100%)
were positive for progesterone receptors. None (0%) of the
six tumors tested positive for PSA markers, and the HER-
2/neu (c-erbB-2) marker was positive in only one (16.6%)
of the six biopsies performed in the 1995-2001 period.
The mean age (62.4) in 21 male patients with breast can-
cer at the time of diagnosis is in accordance with the re-
spective literature data. The percentage of male breast can-
cer vs. female breast cancer was 0.88%, which is compa-
rable with <1% found in other studies. The absence of PSA
positivity in male breast is in agreement with other stud-
ies, suggesting that PSA is not useful as a tumor marker.
The low percentage of HER-2/neu markers (16.6%) as
compared with other similar studies, reporting on 29%
positivity, was most likely the result of the low number of
biopsies taken in consideration.
CORRELATION OF CYTOLOGIC AND
HISTOLOGIC DIAGNOSES OF THE BREAST
I. MariËeviÊ, M. ©okËeviÊ, S. ∆uriÊ-JuriÊ and F. JuriÊ*
Department of Cytology, Sestre milosrdnice University
Hospital, *Zagreb University School of Medicine,
Zagreb, Croatia
Fine-needle aspiration cytology (FNAC) is widely used
in the diagnosis of breast lesions and selection of patients
for surgical treatment. In our Department of Cytology dur-
ing in three-year period FNAC was performed in 1485
patients, in most cases under ultrasound guidance. In a
group of 124 women who underwent surgical treatment at
our hospital, preoperative cytologic findings were malignant
in 73 cases, benign in 47 cases, and 4 specimens were in-
adequate. Postoperative histology found 80 carcinomas and
44 benign lesions. The rate of concordance between the
cytologic and histologic diagnoses was high except for the
cases with a cytologic diagnosis of atypical epithelial hyper-
plasia. Statistical analysis revealed the sensitivity of FNAC
for the presence of carcinoma to be 93.50%, specificity
97.77%, positive predictive value 98.63% and negative pre-
dictive value 89.36%. These results confirm that FNAC is
a highly reliable method in the diagnosis of breast lesions.
METASTASIS OF BREAST CANCER TO
UTERINE CERVIX: A CASE REPORT
AND REVIEW OF THE LITERATURE
M. Eræen, M. Lenart, I. Koπorok, J. ©inkovec, N.
Puhan, M. »aviÊ, D. KopaË
Dept. of Obstetrics and Gynecology, University Medical
Centre, Ljubljana, Slovenia
A patient with abnormal cervical cytology resulting in
the detection of breast cancer metastasis is presented, and
the literature on breast cancer metastasis to the uterine cer-
vix (BCMC) was updated until March 2002, with special
emphasis on the clinical and cytopathological diagnosis.
A 60-year-old woman was repeatedly referred to gyne-
cologist during 6 years after menopause, because of post-
menopausal symptoms, bleeding and discharge, atrophic
vaginitis and abdominal pain. Endometrial curettage re-
vealed no malignancy. PAP test was negative during these
6 years. However, the last cervical smear revealed border-
line glandular cells. After 5 months, the repeated smear
revealed severely dyskaryotic glandular cells with clear
background, and the patient was referred to cervical curet-
tage and biopsy. In the biopsy, subepithelial stroma was
diffusely infiltrated by small cancer cells arranged in a
distinctive single file pattern. Cancer cells stained positive
for cytokeratin. The arrangement of neoplastic cells was
essentially different from the usual infiltration pattern of
squamous cell- or adenocarcinoma, and metastases of
breast cancer (lobular histologic type) was suspected. At
clinical examination, bilateral multiple tumors of the
breast were detected metastases in bone and lungs were
confirmed on x-rays. The patient was treated by chemo-
therapy and hormonal treatment, but she died 22 months
after the diagnosis. BCMC is a rare phenomenon. Simi-
lar to other uncommon secondary tumors of uterine cer-
vix, they may be overlooked on the differential diagnosis
of usual disorders of the genital tract. On the Medline
search, 50 reported cases of BCMC were collected.
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Twenty-seven cases were found in the reports reviewed
from 1950 to 1999. In 21% of these, metastases were found
before or at the same time as the primary tumor. The most
common clinical symptom was abnormal vaginal bleeding
(57%), also present in our patient. However, 32% of the
patients were without clinical signs of cervical malignancy,
and 41% of cases were only found at autopsy. The statement
that more than 80% of primaries with uterine metastases
are of the invasive lobular type was not supported by the ob-
servations of other authors. Pap test failed to reveal cervi-
cal metastasis in one third of the cases. Analysis of 33 Pap
smears with the cells originating in extrauterine carcinomas,
confirmed histologically, showed that the ovary, gastrointes-
tinal tract and breast were the most frequent primary sites
(85% of cases). Several studies have indicated that the lack
of tumor diathesis is characteristic of metastatic carcinoma,
a notion not supported by the others.
It is generally agreed that BCMC is rare, occurs in the
advanced stage of the disease and poses diagnostic prob-
lems. Pap test can serve as a diagnostic tool as well as an
adjunct test to staging and patient’s treatment.
BASIC PATHOLOGIC FINDINGS IN BREAST
CARCINOMA DURING A FIVE-YEAR PERIOD
J. BeziÊ, S. TomiÊ, A. AlujeviÊ, B. VrbiËiÊ
Department of Pathology, Split Clinical Hospital, Split,
Croatia
Aim of the study: As a result of the use of screening
mammography, many breast biopsies are now performed
for small, non palpable, mammographically detected ab-
normalities. In contrast to breast biopsies in the premam-
mographic era, breast biopsies for mammographic abnor-
malities contain a greater number of small invasive can-
cers (minimal breast cancer), in situ carcinomas, tubular
carcinomas and atypical hyperplasias. Twenty-five years
ago, only 3%-5% of all breast cancers were ductal in situ
carcinomas (DCIS), almost exclusively of comedo high-
grade type. Presently the proportion of breast carcinomas
diagnosed as DCIS has increased to 15%-40% of all breast
cancers in screening centers, and these DCIS are predomi-
nantly of non-comedo type. The aim of this study was to
estimate the proportion of in situ carcinomas and small
invasive cancers as well as other basic histopathologic fea-
tures of breast carcinomas surgically removed at the Split
Clinical Hospital during a 5-year period. We analyzed the
basic pathologic features of 942 breast carcinomas, oper-
ated at the Split Clinical Hospital, in the 1997-2001 pe-
riod. We divided the tumors into four groups according
to their greatest diameter: tumors with diameter ≤1 cm,
1-2 cm, 2-3 cm, and with greatest diameter >3 cm. Car-
cinomas were classified into the usual histologic types, and
tumor grade was assigned according to the Bloom-
Richardson grading system. Tumors with positive one or
more lymph nodes at all axillary levels were considered
node positive. The number of operated carcinomas at the
Split Clinical Hospital was 181 in 1997 and 1998, 190 in
1999, 183 in 2000 and 207 in 2001. The rate of small in-
vasive cancers (≤1 cm) was 16.07%. The highest percent-
age was found in the group of the tumors with greatest
diameter of 1-2 cm (35.71%), followed by the group with
a diameter of 2-3 cm (25.56%) and >3cm (22.21%). There
were 69.83% of ductal invasive carcinomas, 10.70% of
lobular carcinomas, and 4.1% of mixed ductal and lobu-
lar carcinomas. The rate of in situ carcinomas was only
3.24%, with a predominance of high and intermediate
grade of ductal in situ carcinomas. The highest number of
carcinomas were moderately differentiated (42.51%),
33.57% of tumors were well differentiated and 23.91% of
tumors were poorly differentiated. There were 49.82% of
node positive patients. Our results showing a small pro-
portion of breast carcinomas diagnosed as in situ carcino-
mas, and small proportion of minimal invasive breast can-
cer are similar to the results in the premammographic era
in the western world. Better results on this issue can be
achieved by organization of screening centers and by
achieving highest percentage of mammographic screen-
ing in the female population.
MACROPHAGE LEVELS AND PARENCHYMAL
EXPRESSION OF MONOCYTE CHEMOTACTIC
PROTEIN-1 IN HUMAN INVASIVE DUCTAL
BREAST CARCINOMA
T. ValkoviÊ1, S. ©tifter2, M. Hasan3, F. Dobrila4, N. JonjiÊ2
1Departments of Internal Medicine, 2Pathology, 3Histol-
ogy and Embryology, and, 4Surgery, Medical School,
University of Rijeka, Rijeka, Croatia
Tumor associated macrophages (TAM) are a population
of mononuclear-phagocytic cells, which can express com-
plex functions related to tumor biology. Monocyte chemo-
tactic protein-1 (MCP-1) is a chemokine involved in the
macrophage infiltration of tumor tissue. The aim of this
study was to define the TAM level and the parenchymal
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MCP-1 expression by immunohistochemical analysis in 97
invasive ductal breast carcinomas NOS; to investigate their
possible relationship and to correlate their values with tu-
mor size, grade, mitotic activity index (MAI), lymph node
status and microvessel density (MVD). Furthermore, the
expression and quantification of MCP-1 mRNA were de-
termined by reverse transcriptase-polymerase chain reaction
(RT-PCR) in 8 samples of invasive ductal breast carcino-
mas, 3 fibroadenomas and 8 samples of normal breast tis-
sues. MCP-1 immunoreactivity was present in tumoral
cells, but also in TAM, fibroblasts and endothelial cells.
Statistical analysis did not show significant correlation be-
tween MCP-1 expression in tumoral epithelium and tumor
size, grade, MAI, lymph node status, MVD, and TAM,
while TAM showed a connection with tumor proliferation
(MAI) (p<0.001) and MVD (p=0.008). In all cases of breast
carcinomas (8/8) and in the majority of fibroadenomas (2/
3) and normal breast tissues (7/8), the MCP-1 mRNA was
detected by RT-PCR. It can be concluded that TAM play
a protumoral role in invasive breast carcinoma NOS by
promoting tumor proliferation and angiogenesis. Accord-
ing to immunohistochemical analysis, these results indicate
that MCP-1 is not crucial for macrophage attraction to
tumor locus in breast carcinoma but it must be pointed out
that immunohistology is not the method of choice for es-
timating the chemoattractant potential of MCP-1. The
results of RT-PCR indicate that all cases of breast carcino-
mas expressed MCP-1 mRNA in generally higher levels
than non-malignant breast tissues. RT-PCR is a very good
and objective method for determining the production of
MCP-1 in tumors, or more precisely their mRNA.
RELATIONSHIP BETWEEN ABO BLOOD
GROUPS AND PRIMARY BREAST
CANCER PROGNOSIS
Mohammad Reza Jalali Nadooshan*, Hamid Reza
Taheri*, Naser Valaei**
*Shahed University, **Shahid Beheshti University of
Medical Science, Tehran, Iran
Breast cancer is the most common cancer in females,
and multiple factors contribute to the prognosis of this
cancer, one of the suggested being blood groups. There-
fore, this study was designed to determine the relationship
between ABO blood groups and prognosis.
This case-control study was performed in 200 patients
(100 controls and 100 cases) and 1000 healthy persons
without breast cancer as a second control group. Control
group patients with good prognosis had tumor size less
than 2.5 cm without axillary node involvement, and case
group with poor prognosis had tumor size greater than 2.5
cm with at least one axillary node involved. Patient blood
groups were derived from their medical files.
Blood groups B and AB were more prevalent in the
poor prognosis patients than in other groups. Antigen B
was found in the control group (30.5%) and case group
(45%). OR equaled 1.8 in this study. The probablity of
poor prognosis in those patients with breast cancer who
expressed AgB ranged from at least 1.2 to up to 2.8-fold
that in the general population.
It is concluded that blood group antigen B correlates
with poor prognosis of breast cancer, and evaluation of its
role requires further prospective studies with patient fol-
low-up.
RELATIONSHIP BETWEEN PATIENT AGE,
GRADE OF BREAST CANCER AND
DISEASE PROGNOSIS
Mohammad Reza Jalali Nadooshan*, Hamid Reza
Taheri*, Naser Valaei**
**Shahid Beheshti University of Medical Science,
*Shahed University, Tehran, Iran
Concerning the prevalence of breast cancer and its well-
known prognosis as well as the role of patient’s age and
disease grade in the prognosis, and in order to determine
the relationship of grade and age with prognosis, we per-
formed a study in patients referred to 3 university hospi-
tals during 7 years. This case-control study included 200
patients with breast cancer: 100 cases were selected on the
basis of involvement of at least 1 lymph node, and tumor
size greater than 2.5 cm (case=poor prognosis) and another
100 patients selected on the basis of absence of the above
criteria (control=good prognosis). Grading based on
Bloom-Richardson criteria was identified. The mean age of
control group patients was 42.5±8.8, and of case group
53.4±12.2 yrs, yielding a 25.6% difference. Also, develop-
ment of breast cancer at age > 50 may increase the prob-
ability of poor prognosis by 17 times. The probability of
poor prognosis in grade III was 5.6-fold that found in grade
I. Age and grade both influence the prognosis of breast
concer and other studies with patient follow-up are recom-
mended.
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PROGNOSTIC SIGNIFICANCE OF LYMPHATIC
AND BLOOD VESSEL INVASION BY TUMOR
CELLS IN COLORECTAL CARCINOMA
S. TomiÊ, S. AnelinoviÊ, L. Puljak*, V. PeπutiÊ-Pisac, J.
BeziÊ, K. MilostiÊ, G. Trgo*
Department of Gastroenterology, *Department of
Pathology, *Departmant of Urology, Split Clinical Hospital,
Split, Croatia
This study was undertaken to examine the prognostic
value of lymphatic and blood vessel invasion by tumor cells
in colorectal carcinoma. In this study, 100 patients with
colorectal carcinoma were examined. Vessel invasion by
tumor cells was examined in formalin fixed, paraffin em-
bedded tissue using standard hemalaun-eosin method,
Verhoeff method and immunohistochemistry (anti-hu-
man von Willebrand’s factor, DAKO, EPOS). Vessel in-
vasion by tumor cells positively correlated with higher
tumor grade (p=0.0001), Dukes stage (p=0.0001), occur-
rence of metastatic disease in 5-year period (p=0.0001),
and lower 5-year survival (p=0,0001). Lower 5-year sur-
vival rate was observed in patients with vascular invasion
considering correction of the stage too (Dukes B: p=0.018;
Dukes C: p= 0.0002). However, when we compared 5-year
survival period in patients with Dukes stage B and Dukes
stage C when blood vessel invasion was confirmed, we did
not find any statistically significant difference (p=0.62).
Lymphatic and blood vessel invasion may be independent
prognostic criteria in patients with colorectal carcinoma.
Moreover, it seems that using this parameter it is possible
to separate a subgroup of patients with colorectal carci-
noma in Dukes B stage with worse prognosis who need
postoperative adjuvant therapy.
MESENCHYMAL PANCREATIC TUMORS
G. Cecchetto, R. Cecchetto, C. Clemente, G.
Marchesini, A. Pennelli, Galligioni
Istituto di Anatomia Patologica, Padua, Italy
Mesenchymal pancreatic neoplasias are extremely rare,
compared with the epithelial, neuroendocrine or cystic
ones, and occasionally their histogenesis may not be for
sure assessed even by immunohistochemistry. The most
conspicuous casuistics is that of Ferrozzi et al. from 2000,
including 2 lymphangiomas, 2 lipomas, 4 schwannomas,
1 neurofibroma, 2 leiomyosarcomas, 1 undifferentiated
sarcoma and 9 non-Hodgkin lymphomas. Apart from this
study, in the literature we found only isolated case reports.
In the last four years, we observed 446 pancreatic lesions
in adults: 1 liposarcoma (diagnosed by aspiration cytology
and successively confirmed by histology), 1 spindle cell
sarcoma, 262 adenocarcinomas, 56 neuroendocrine tu-
mors, 18 cystic lesions, 83 pancreatitis, 23 pseudocysts, 13
tumors of the Vater ampulla, 5 pancreatic infiltrations of
lymphoma, and 3 of leiomyosarcoma. The pathologist
must be very careful in the diagnosis of primary pancre-
atic sarcoma, as most of them are spindle cell carcinoma
or pancreatic infiltration of retroperitoneal sarcomas.
ESOPHAGEAL HEMANGIOPERICYTOMA AS
AN ACCIDENTAL ENDOSCOPIC FINDING.
A CASE REPORT
D. BaliËeviÊ1, I. Novosel2, D. Hrabar3
1Ljudevit Jurak Department of Pathology, Sestre
milosrdnice Universitiy Hospital, Zagreb
2Department of Pathology, Dr Ivo PediπiÊ County
Hospital, Sisak
3University Department of Medicine, Sestre milosrdnice
Universtity Hospital, Zagreb, Croatia
Hemangiopericytoma is a rare malignant vascular tu-
mor that derives from pericytes. It is common in extremi-
ties and retroperitoneum, but extremely rare in gastroin-
testinal tract.
According to recent literature, only two cases refer to
esophageal localization. We report the first case of heman-
giopericytoma in the gastroesophageal region. A 56-year-
old patient presented to the gastroenterologist for dyspep-
tic problems. As recommended therapy with H2-recep-
tor antagonist showed no improvement, gastroendoscopy
was done. By visual inspection, ventricular mucosa ap-
peared slightly reddish, but with normal rugal folds.
A prominent and accidental finding was a polypoid
mass located at the very gastroesophageal border. It looked
like a sesile polyp of coin size, grayish, with rough surface.
During the same act, biopsy of gastric mucosa in the re-
gion suspect of chronic gastritis as well as polypectomy
were performed.
Pathohistologic examination confirmed chronic gas-
tritis. The tumor-like mass had a characteristic staghorn
appearance of capillary branches, sourrounded by nests of
ovoid cells, with no mitosees. Silver impregnation showed
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extremely positive reaction, while immunohistochemical
staining revealed negative reaction to cytokeratin and
CD34.
As hemangiopericytoma is an uncommon vascular neo-
plasm with a vascular pattern similar to many other tumors,
it is usually diagnosed by exclusion. The following param-
eters should be included: vasculature, histologic pattern,
degree of cellular pleomorphism, necrosis, mitoses and gi-
ant cell content. Immuno histochemistry is crucial for the
accurate diagnosis of hemangiopericytoma.
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HCV-LIKE HCV-NEGATIVE HEPATITIS IN OLT
A. Cecchetto, G. Cecchetto, R. Clemente,
C. Marchesini, G. Pennelli, A. Galligionistituto di
Anatomia Patologica, Padua, Italy
HCV infection is the most frequent event in a trans-
planted liver, both in HCV-positive and HCV-negative
recipients. In long-term follow-up, the recurrence rate of
HCV is from 87% to 100% of transplanted livers, and
within 1 year, 32% to 100% of the patients are affected by
acute or chronic hepatitis or cirrhosis. Histologic lesions
in OLT may be observed even without any clinical or se-
rologic marker, because of immunosuppressive therapy,
and HCV DNA can be detected by PCR analysis before
or without an antibody response. Moreover, 10% of HCV
negative recipients may be infected by blood transfusion
during transplantation or by the presence of HCV in the
donor tissues. The morphological features of HVC hepa-
titis in a transplanted liver are quite modified by immu-
nosuppressive therapy; differential diagnosis includes a
large spectrum of OLT-related pathology such as HBV in-
fection, cellular rejection, recurrence of PBC, and oppor-
tunistic infections. In more than 560 OLT performed in
Padua, almost one half of the patients were not HCV posi-
tive, and among them we observed 11 cases ∑ 3 pediatric
- affected by HCV-like HCVC-negative hepatitis. TTV
was found in 2 out of 6 cases. In our opinion, the detec-
tion of TTV does not necessarily mean that it is the virus
responsible for HCV-like HCVC-negative hepatitis, as it
is widespread and inconstantly hepatotoxic.
MUCINOUS COLORECTAL CARCINOMAS IN
BIOPSIES, 1996-2001
D. BrezoveËki-Biin1, D. BaliËeviÊ1, D. Tomas1,
L. TuzoviÊ1, M. ©karica1, N. Bulj1, S. HrkaË-KneæeviÊ1,
D. Ciglar1, V. RadotiÊ1, T. LeniËek1, M. GlasnoviÊ1,
D. KovaËeviÊ2 and M. Belicza1
Ljudevit Jurak University Department of Pathology 1
University Department of Surgery2
Sestre milosrdnice University Hospital, Zagreb, Croatia
SUMMARY ∑ Mucinous colorectal carcinomas show
some clinicopathological characteristics that are not found
in nonmucinous carcinomas. A total of 1451 colorectal car-
cinomas were analyzed. Carcinomas were divided into two
groups according to the presence or absence of mucinous
content. Then, three independent pathologists reviewed all
slides with carcinomas with mucinous content by micro-
scopic morphometry and divided them into two subgroups:
mucinous carcinomas (>50% mucin) and colorectal carci-
nomas with mucin (<50% mucin). The following param-
eters were analyzed: share of mucinous colorectal cancer and
cancer with mucin, sex and age distribution of all three
groups of carcinomas, and localization and Dukes stage of
mucinous carcinomas and carcinomas with mucin. Muci-
nous carcinomas were confirmed to have poorer prognosis,
predilection for younger age group, higher incidence in the
proximal colon, and no male predomination. Colorectal
carcinomas with mucin had some characteristics of both
mucinous cancer and nonmucinous cancer, and could be
positioned somewhere in between these two different
groups.
Key words: colorectal carcinoma, mucinous colorectal car-
cinoma, colorectal carcinoma with mucin
Introduction
The rates of colorectal cancer incidence vary consid-
erably when observed worldwide, according to sex, age and
anatomic subsite, and have changed over time1. In Europe,
especially in eastern countries, and in the United States,
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colorectal cancer is on the second place of all cancer-re-
lated deaths. About 98% of all colorectal tumors are ad-
enocarcinomas. Many of them produce different amounts
of mucin, which is secreted into the gland lumen or into
the gut wall2. Mucinous colorectal carcinomas are defined
on the basis of the amount of the mucus component in the
tumor mass, and the term mucinous carcinoma may only
be applied to the carcinomas that contain ≥ 50% of the
mucinous component3. The role of a large extracellular
mucinous component in colorectal carcinomas continues
to be controversial. In some authors’ opinion, these tumors
have a predilection for younger age groups, involve the
more proximal colon, there is no male predomination, are
more advanced at diagnosis, and have a poorer prognosis
than nonmucinous colorectal carcinomas4. The poorer
prognosis and aggressive clinical course are directly influ-
enced by the percentage of mucinous component5. Apart
from this quantitative criterion, some genetic alterations
(e.g., frequency of mutation ki-ras and p-53 genes, level
of Muc2 expression) also differentiate these tumors from
the nonmucinous ones6-8. The purpose of this report is to
analyze some clinicopathologic features of mucinous
colorectal carcinomas in our environment. We compared
colorectal cancer with and without mucinous content, and
also the same parameters within the group of colorectal
cancer with mucinous content according to the amount of
mucin (>50% of mucinous content and <50% of mucinous
content). The following parameters were analyzed: share
of mucinous colorectal cancer and cancer with mucin, sex
and age distribution of all three groups of carcinomas, and
localization and Dukes’ classification of mucinous carci-
nomas and carcinomas with mucin9.
Patients nad Methods
Patient data were obtained from the computer based
colorectal cancer registry at the Ljudevit Jurak University
Department of Pathology, for the period between Janu-
ary 1, 1996 and December 31, 2001. A total of 1451
colorectal carcinomas were analyzed. Formalin fixed, par-
affin embedded tumor tissue was cut at 5-mm sections,
deparaffinized, stained with hematoxylin and eosin, and
examined for the presence of mucin. Carcinomas were
divided into two groups according to the presence or ab-
sence of mucinous content. Then, three independent pa-
thologists reviewed all slides with carcinomas that had
mucinous content by microscopic morphometry and di-
vided them into two subgroups: mucinous carcinomas and
Fig. 1. Percentage of mucinous colorectal carcinomas and carcinomas
with mucin from 1996 till 2001.
colorectal carcinomas with mucin. When 50% or more of
high-power fields examined consisted of mucinous tumor
tissue, the term mucinous carcinoma was applied. For car-
cinomas with less than 50% of mucinous content the term
“carcinoma with mucin” was applied3.
Results
We detected 160 (11%) colorectal carcinomas with
mucinous content, 95 (6.5%) mucinous carcinomas, and
65 (4.5%) carcinomas with mucin. The share of mucinous
colorectal carcinomas and carcinomas with mucin in-
creased over the 6-year period from 4.4% to 14.9% (Fig.
1). The male/female ratio was lower in mucinous carcino-
mas and carcinomas with mucin than in carcinomas with-
out mucin, except for the year 1996 when the male/female
ratio was 3.5. In 1999, the number of female patients with
mucinous colorectal carcinoma and carcinoma with mu-
cin was higher than the number of male patients (male/
female ratio 0.9) (Fig 2). The mean age of patients with
mucinous colorectal carcinoma and carcinoma with mu-
cin was slightly lower than the mean age of patients with
carcinoma without mucin. The mean age of patients with
mucinous cancer and cancer with mucin was lowest in
1996 (only 61.3 years) and highest in 1998 (69.7 years).
Comparison of the mean age of all three groups of patients
(mucinous carcinomas, and carcinomas with and without
mucin) revealed it to be lower in patients with mucinous
carcinomas than in other patient groups, but similar in
patients with carcinomas with mucin and those with car-
cinomas without mucin (Fig. 3). Mucinous carcinomas
and carcinomas with mucin were predominantly located
in the rectum (>40%), followed by ascending and sigmoid
colon with an almost identical percentage of cases (∼20%),
and then transverse colon (∼10%). Localization remained
unknown for 5.2% of mucinous carcinomas and 6.2% of
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carcinomas with mucin (Fig. 4). Comparison of Dukes
classification between mucinous carcinomas and carcino-
mas with mucin showed more mucinous carcinomas to be
in Dukes stage C (62.1%) on detection. Also, many of
these were in Dukes stage B (23.2%), and only 8.4% and
6.3% were in Dukes stage A and AC, respectively. On the
other hand, 33.9% of carcinomas with mucin were in
Dukes stage C at the time of detection. A similar num-
ber of carcinomas with mucin were in Dukes stage A, AC
and C (30%). A smaller number of carcinomas with mu-
cin were in Dukes stage B (7.7%) (Fig. 5).
Discussion and Conclusion
Some studies have indicated that a finding of muci-
nous carcinomas may be an adverse prognostic factor, af-
fecting on an average younger patients, showing no male
predomination, and having poorer prognosis. This poorer
prognosis and aggressive biological behavior of mucinous
carcinomas were directly connected with the mucinous
component6-8. In some other studies, an association with
decreased survival was demonstrated only when mucinous
carcinomas and signet ring cell carcinomas were grouped
vith mucin without mucin
Fig. 2. Male/female ratio in carcinomas with mucinous content (all























Fig. 3. Mean age of patients with mucinous carcinomas, carcinomas
with mucin and carcinomas without mucin.


























Fig. 4. Distribution of mucinous carcinomas and carcinomas with













Fig. 5. Comparison of Dukes stage of mucinous carcinomas and car-
cinomas with mucin.
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together and compared to non-mucinous carcinomas.
However, data on this type may be merely a reflection of
the aggressive clinical course of signet ring cell carcino-
mas10. According to these authors, the mucinous histo-
logic type itself was not an independent prognostic fac-
tor in colorectal carcinomas11.
The results presented show an increased number of
mucinous colorectal carcinomas and carcinomas with mu-
cin. The share of these types of tumor increased more than
3-fold during the observed period. The results also showed
that there was no strong male predominance for this type
of colorectal carcinoma, and female had an almost iden-
tical risk for this tumor type. The population affected with
mucinous colorectal cancer were in general younger than
the population who had cancer without mucinous content.
The median age was approximately the same in patients
with carcinoma with mucin and those with nonmucinous
carcinoma. Comparison of mucinous cancer and cancer
with mucin revealed an almost identical distribution of the
two types and confirmed their higher incidence in proxi-
mal colon than of carcinomas without mucinous content.
Comparison of Dukes staging between mucinous carci-
nomas and carcinomas with mucin showed higher Dukes
stage in mucinous carcinomas at the time of detection,
which may be related to the amount of mucinous content.
We confirmed that mucinous carcinomas had poorer prog-
nosis, predilection for younger age group, higher incidence
in proximal colon, and no male predomination, however,
the group of mucinous cancers also included signet ring
cell carcinomas. Colorectal carcinomas with mucin had
some characteristics of both mucinous cancer and
nonmucinous cancer, and could be positioned somewhere
in between these two groups. Further epidemiological
studies are needed to assess the true behavior of colorectal
carcinomas with less than 50% of mucinous content, and
effects of signet ring cell carcinoma on some of the param-
eters examined in this study.
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Saæetak
Mucinozni adenokarcinomi debelog crijeva se po nekim
svojim kliniËko-patoloπkim obiljeæjima razlikuju od nemucino-
znih adenokarcinoma. Napravljena je revizija svih karcinoma
debelog crijeva od 1996. do 2001. godine. Karcinome s
mucinoznim sadræajem dodatno su pregledala tri neovisna
patologa te su podijeljeni u dvije podskupine: mucinozni
karcinomi (viπe od 50% sluzi) i karcinomi s mucinom (manje
od 50% sluzi). Dobiveni rezultati pokazuju poveÊanje udjela
karcinoma s mucinoznim sadræajem u ukupnom broju
kolorektalnih karcinoma. Predispozicija obolijevanja od
karcinoma s mucinoznim sadræajem podjednaka je za oba spola
dok su muπkarci ËeπÊe obolijevali od nemucinoznih karcinoma.
Usporedba prosjeËne dobi pokazala je da su bolesnici s
mucinoznim karcinomima prosjeËno mlai od onih s ne-
mucinoznim i karcinomima s mucinom. Lokalizacija mucino-
znih karcinoma i karcinoma s mucinom je bila podjednaka i
primjetan je pomak u desni dio kolona. Usporedba Dukesove
klasifikacije mucinoznih karcinoma i onih s mucinom pokazala
je da se u trenutku dijagnosticiranja veÊina mucinoznih karci-
noma nalazi u Dukesovu stadiju C, za razliku od karcinoma
s mucinom kojih je u Ëasu dijagnosticiranja bilo podjednako
u Dukesovu stadiju A, AC i C bolesti. Dobiveni rezultati
pokazuju da se po nekim svojim obiljeæjima mucinozni kar-
cinomi razlikuju od nemucinoznih, dok karcinomi s mucinom
posjeduju neke osobitosti i jednih i drugih.
KljuËne rijeËi: karcinomi debelog crijeva, mucinozni karcinomi,
karcinomi s mucinom
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INCIDENCE OF HISTOLOGIC PATTERN AND
ANATOMIC DISTRIBUTION OF COLORECTAL
CARCINOMA (1989-2001)
D. BrezoveËki-Biin, D. BaliËeviÊ, D. Tomas, L. TuzoviÊ,
M. ©karica, N. Bulj, S. HrkaË-KneæeviÊ, D. Ciglar,
V. RadotiÊ, M. GlasnoviÊ, T. LeniËek, M. Belicza
Ljudevit Jurak University Department of Pathology,
Sestre milosrdnice University Hospital, Zagreb, Croatia
The aim of this study was to examine the incidence of
colorectal carcinoma during a 13-year period according to
histologic pattern, anatomic localization, and sex and age
distribution. This study was also linked to our previous
study where colorectal carcinomas were divided according
to the prewar, war and postwar periods, as we wanted to
compare some basic conclusions.
A total of 2559 patients with colorectal cancer were
analyzed. Patient data were obtained from the computer
based colorectal carcinoma registry established at the
Ljudevit Jurak University Department of Pathology, Sestre
milosrdnice, University Hospital, Zagreb, Croatia. We
examined the total number of colorectal carcinoma and
their incidence in all biopsies made during the 13-year
period, share of mucinous colorectal carcinomas, sex dis-
tribution, mean age, and anatomic localization, where
carcinomas were divided into four subgroups: right sided
(cecum and colon ascendens), transverse (transverse co-
lon), left sided (descendent colon, sigma and rectum), and
unknown localization.
During the study period, 148699 biopsies were made,
and 2559 or 1.7% were colorectal carcinomas. The inci-
dence of colorectal carcinomas slightly increased between
1989 and 1993 but from 1994 this trend rose faster and
in 2001 the number of colorectal carcinomas was two fold
than in 1989 (Fig 1). The mean share of mucinous carci-
nomas was 6.5% (n=166), varying from 0.6% in 1990 to
16% in 1993 (Fig. 2.). The mean age ranged from 62.1
years in 1990 to 68 years in 1995, with overall mean for
the study period of 65.6 years (Fig 3). Sex distribution
showed male predominance (58.6% vs. 41.4%) (Fig. 4).
Left-sided cancers were most common (66.1%) followed
by right-sided (8.7%) and transverse colon cancers (6.2%).
In 19.3% of cases the localization of colorectal carcinomas
remained unknown (Fig 5).
The results showed a significant increase in the inci-
dence of colorectal carcinomas, especially in the last nine
years. The rate of mucinous carcinomas altered with two
unexplainable peaks in 1993 and 1994, when the total
Fig. 1. Incidence of colorectal carcinoma 1989-2001.
Fig. 2. Incidence of mucinous colorectal carcinoma 1989-2001.
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INFLUENCE OF DIFFERENTATION GRADE
EXPRESSED BY GLEASON SCORE ON SUR-
VIVAL IN PROSTATE CANCER PATIENTS
K. MilostiÊ, S. TomiÊ, G. Trgo, I. OlujiÊ
Department of Urology and Department of Pathology,
Split Clinical Hospital, Split, Croatia
Through a retrospective clinical study we present the
influence of differentation grade (Gleason score) on survival
in patients with prostate cancer. The study included opera-
tive material of 50 prostate cancers, overall age 72.5 (51-87)
years. The patients were operated on with transurethral
resection (35%-70%) and classic transvesical adenomectomy
(15%-30%). After histologic analysis, Gleason score was
determined. The patients were classified in three groups:
well (Gleason score 2, 3 and 4), moderately (Gleason score
5, 6 and 7) and poorely differentiated carcinomas (Gleason
score 8, 9 and 10). Comparison of survival of patients with
well and moderately differentiated carcinomas showed no
statistically significant survival difference (log rank=3.41;
p=0.065). Comparison of survival of patients with moder-
ately and poorely differentiated carcinomas revealed no sta-
tistically significant survival difference either (log rank=2.09;
p=0.148). However, comparing the groups with well and
poorly differentiated carcinomas, a statistically significant
difference (log rank=14.7; p=0.0001) was found. Because of
that, we separated moderate group of the carcinomas with
a cut off-7 and obtained high statistical significance in sur-
vival (log rank=8.73; p=0.031). Patients with Gleason score
2-6 had average survival of 94 months, but patients with
Gleason score 7-10 had average survival of only 47 months.
Univariate analysis of the differentiation grade showed the
high statistical significance to be a prognostic factor in pa-
tients with prostate carcinoma. Differentiation grade is
clinically useful to identify tumors with poor and good bio-
logical behavior, as well as patients in whom there is a good
reason for radical surgery and adjuvant postoperative
therapy.
Fig 5. Localization of colorectal carcinoma 1989-2001.
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number of colorectal carcinomas slightly decreased. The
mean age and sex distribution were as expected and close
to recent literature data. The localization was also as ex-
pected, however, a slight decrease in left sided carcinoma
during the 13-year period was obvious. In conclusion, the
study pointed to the significant increase in colorectal car-
cinoma in our population, with no significant change in
age and sex distribution, and a slightly decreased incidence
of rectosigmoidal cancer, which is a trend noticed in west-
ern countries some years before. The obtained data also
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MULTIVARIATE STATISTICAL ANALYSIS
OF MOLECULAR DATA ON APC AND CDH1
GENE INVOLVEMENT IN RENAL CELL
CARCINOMA AND CLINICAL PARAMETERS
OF THE DISEASE
N. PeÊina-©laus1, K. Gall-Troπelj2, K. PaveliÊ2, J.
PaveliÊ2
1Department of Biology, School of Medicine, University
of Zagreb, 2Division of Molecular Medicine, Ruer
BoπkoviÊ Institute, Zagreb, Croatia
When investigating cancer at the molecular level, data
obtained by the methods of molecular biology are usually
compared and correlated with only one clinical parameter
at the time resulting in one-dimensional approach to sta-
tistical analysis. The employment of multivariate statisti-
cal methods simultaneously correlates and weighs all in-
vestigated parameters offering new insights into the prob-
lem. In this paper, the data obtained investigating renal cell
carcinoma (RCC) at the molecular level were analyzed by
the multivariate statistical method (principal components)
together with clinical parameters: TNM stage, histopatho-
logic grade, age and sex.
Molecular analysis was confined to genetic instabilities
of renal cell carcinoma regarding the roles of two tumor
suppressor genes (adenomatous polyposis coli, APC and E-
cadherin, CDH1). Both gene products are components of
adherens junction, where E-cadherin is bound to (β-catenin
which in turn binds to the central part of the APC protein1.
Besides their structural roles in cellular architecture, protein
products of APC and CDH 1 genes play signaling roles in
the wnt signal transduction pathway2,3.
Mutations in the adenomatous polyposis coli gene are
responsible for the disease familial adenomatous polyposis
(FAP) and the majority of sporadic colorectal cancer, but
are also found in a large variety of other cancers4. The other
gene investigated, E-cadherin, is one of the most impor-
tant molecules of cell-cell adhesion in epithelial tissues. It
is a member of a large family of genes that code for calcium-
dependent-cell-adhesion-molecules (CAMs) and is gener-
ally localized on the surface of epithelial cells5. A number
of epithelial cancers demonstrate loss of expression as well
as mutations of E-cadherin gene. Recently a tumor inva-
sion/suppressor role has been assigned to this gene.
Forty-five human renal cell carcinomas were tested for
APC gene instability by polymerase chain reaction/loss of
heterozygosity (LOH) using RFLP method6. E-cadherin
gene (CDH1) was analyzed by PCR amplification of
tetranucleotide marker (D16 S752) and the alleles were
visualized by PAGE/silver staining. The overall propor-
tion of LOH cases of the APC gene was 37.5% (9/24)
(Fig.1). D16 S752 marker linked to E-cadherin gene
(informativity 91%) revealed 3 (7.5%) LOH cases (Fig.
2A). In 10% of RCC samples another type of genomic
instability was detected, replication error (RER) indicat-
ing that another cellular mechanism, mismatch repair, is
targeted in RCC (Fig. 2B).
The results of the multivariate statistical analysis of the
samples informative for both APC and E-cadherin genes
showed that in this data set LOH of the APC gene posi-
tively correlated with advanced age and more severe TNM
stages. Genomic instabilities of the E-cadherin gene, on
the other hand, appear to be correlated with younger age
groups and less severe TNM stages (Fig. 3).
Our results suggest that alterations in APC gene are not
the first event in kidney tumorigenesis, but are involved in
the progression of RCC. Analysis of E-cadherin involve-
ment although less conclusive (because of the lower fre-
Fig. 1. Loss of heterozygosity at APC in renal cell carcinoma.
Exon11/RsaI/RFLP, 13% polyacrylamide gel stained with ethidium
bromide: lane 1 - informative blood sample; lane 2 - LOH in corre-
sponding renal carcinoma (cut allele is missing); lane 3 - molecular
standard (X174 DNA/HaeIII.
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B) Genetic instability (replication error, RER+) of E-cadherin gene
on 15% polyacrylamide gel stained with silver: lane 1 - molecular
standard M3; lanes 2, 3, 8, 9 - heterozygous RCC and correspond-
ing blood samples; lane 4, 5 - homozygous (uninformative) RCC and
blood samples; lanes 6, 10 - RER+ RCC samples; lanes 7, 11- cor-
responding blood samples.
Fig. 2. A) LOH of the E-cadherin gene on Spreadex gel (Elchrom
Scientific) stained with Sybergold (Molecular Probes). Polymorphic
tetranucleotide repeat D16 S752 is shown (informativity 91%).
Lane 1 - molecular marker M3 (Elchrom Scientific); lanes 2, 3, 4,
5, 8, 9, 10, 11, 12, 13 - heterozygous RCC and corresponding blood
samples; lanes 6 - LOH of  E-cadherin gene in RCC sample; lane 7
- corresponding informative blood sample.
Fig. 3. Multivariate statistical analysis. Scatterplot of samples on
first two principal components.
quency of APC changes) suggest that changes in this gene
may be an earlier event. Given that E-cadherin is involved
in diverse mechanisms in the cell it is also possible that the
impairment of its function lies in transcriptional mecha-
nisms.
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VANISHING-BURNED LESION OF TESTICLE
CANCER ∑ TWO CASE REPORTS
K. MilostiÊ S. TomiÊ, M. Glavina-Durdov, G. Trgo, I. OlujiÊ
Department of Urology and Department of Pathology,
Split Clinical Hospital, Split, Croatia
The purpose of this presentation is to show that a tes-
ticular scar should not be ignored in young men, because it
may represent an introduction in testicular cancer. Because
of breathing difficulties the first patient was diagnosed as
having lung cancer and was operated on. Pathohistology:
pulmonary carcinoma of embryonal type. Urological exami-
nation revealed a knotty testicle, and orchiectomy was per-
formed. Pathohistology: scar, hemosiderine pigment,
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hemosiderophages, and mononuclear cell infiltrate without
malignant cells. The second patient underwent orchiectomy
because of trauma to the previously normal testicle with
normal tumor markers. Pathohistology: scar with hemo-
siderine pigment, hemosiderophages and mononuclear cell
infiltrate without malignant cells. After one year, numerous
retroperitoneal lymph node metastases developed, with
strongly elevated AFP and β-HCG markers. It is concluded
that testicular cancers metastasizing in the lung should be
considered in young men, because primary carcinoma is very
rare in this population. In case of trauma to the testicle in
young men, long-term follow-up of tumor markers and
lymph node status is mandatory.
FINE STRUCTURE OF LEYDIG CELLS
IN PATIENTS WITH NON-OBSTRUCTIVE
AZOOSPERMIA
D. Jeæek1, N. KneæeviÊ2, Lj. Banek1, I. Krhen2,
V. MuæiÊ1, S. Kalanj-Bognar3, R. PezeroviÊ-Panijan1,
Z. MarekoviÊ2
1Institute of Histology and Embryology; 2Department of
Urology, 3Institute of Chemistry and Biochemistry,
Medical School, University of Zagreb, Zagreb, Croatia
Leydig cells are situated within the testis interstitium.
These cells are an important source of testosterone, a male
sex hormone that stimulates spermatogenesis. Therefore,
the structural integrity of Leydig cells is necessary for the
normal sperm production. The purpose of the study was to
describe changes of the ultrastructure of Leydig cells in
patients with non-obstructive azoospermia. A total of 44
testicular biopsies from infertile patients with non-obstruc-
tive azoospermia and 8 control biopsies were analyzed. In
control biopsies, Leydig cells showed normal ultrastructure.
A round or oval nucleus was situated mostly in the center
of the cell. The chromatin of the nucleus was predominantly
euchromatic, with a low presence of heterochromatin asso-
ciated with the nuclear envelope. A prominent nucleolus was
frequently observed. The cytoplasm of the cell was rich in
cisternae of smooth endoplasmic reticulum and mitochon-
dria with tubular cristae. Occasional cisternae of rough en-
doplasmic reticulum, glycogen, lipid droplets and Reinke’s
crystals were also observed. Leydig cells in infertile men with
non-obstructive azoospermia had a significantly changed
ultrastructure. The nucleus of such cells was often indented
with the increased presence of heterochromatin. Within the
cell cytoplasm, a lot of lipid droplets and vacuoles of the elec-
tron low-density content could be noticed. There was a re-
duction in the cisternae of smooth endoplasmic reticulum,
glycogen and mitochondria. The presence of Reinke’s crys-
tals seemed to be reduced in the pathologically changed
cells. However, it should be pointed out that all biopsies
contained a limited number of Leydig cells with the nor-
mal fine structure. Leydig cells in patients with non-ob-
structive azoospermia showed significant changes in their
ultrastructure. The cells with normal (unchanged) morphol-
ogy were also observed within the same biopsies, but were
less numerous. Electron microscopic observations on the
fine structure of Leydig cells could help in the understand-
ing of factors contributing to the male-factor infertility.
ULTRASTRUCTURAL ANALYSIS OF SPERMS
WITH IMPAIRED MOTILITY ∑ A CASE REPORT
V. MuæiÊ1, D. Jeæek1, P. CvitkoviÊ2, Lj. Banek1,
P. Romac2, D. LuËinger2
1Institute of Histology & Embryology, School of
Medicine, University of Zagreb
Vuk Vrhovac Institute, School of Medicine, University of
Zagreb, Zagreb, Croatia
Causes of male-factor infertility are often multifactorial
and include various disturbances of sperm motility, i.e.
asthenospermia. Asthenospermia could be a consequence
of anomalies of the sperm head or tail. In severe cases, these
abnormalities could be combined resulting in severe ter-
atospermia, which can be detected at the light microscopic
level. However, only at the electron microscopic level a fine
structure and anomalies of the sperm head and tail can be
analyzed. This case report describes a patient with severe
asthenospermia. A 30-year-old patient had normal sperm
count with extremely poor motility (repeated spermato-
grams). On an average, 97% of the sperms were immotile
and 85% were polymorphic, as recorded by the computer-
aided semen analysis. In order to perform an electron mi-
croscopic analysis, the ejaculate (minimum 3 days of ab-
stinence, ~3 ml) was fixed in 4% glutaraldehyde (in 0.1 M
phosphate buffer), postfixed in 1% OsO4, dehydrated and
embedded in Durcopan. Semithin and ultrathin sections
were prepared by Reichert ultramicrotome. Ultrathin sec-
tions were placed on copper grids, contrasted and examined
by a Carl Zeiss 902A electron microscope. Many sperms
manifested various abnormalities of the head and tail. Nor-
mally structured sperms were only sporadically found. Ab-
normal sperms had often a globular appearance of the head
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with a defect of chromatin condensation. Thus, the head of
such sperms was by 2-3 µm bigger than in normal sperm.
Within the chromatin of the head, sometimes membrane-
like inclusions could be seen. Residual body, instead of be-
ing phagocitozed, was often found attached to the nucleus.
The acrosome showed various malformations and/or was
smaller than usual. The tail also showed several types of ab-
normalities. The mitochondria within the proximal part of
the tail were frequently missing, or the number of mitochon-
dria was significantly reduced. The constellation of micro-
tubules was disturbed in such a manner that the central pair
of microtubules did not occupy the central position within
the tail and was pushed aside. It is concluded that the ul-
trastructural analysis of semen sample could provide useful
information on the sperm morphology. However, the elec-
tron microscopic examination of the semen should be done
in strictly selected cases.
PERIACINAR CLEFT-LIKE SPACES IN
PROSTATIC NEEDLE CORE BIOPSIES
B. Kruπlin1, I. Novosel2, A. ReljiÊ3, H. »upiÊ1, B. SpajiÊ3,
M. Belicza1
1Ljudevit Jurak University Department of Pathology,
Sestre milosrdnice University Hospital, Zagreb;
2Department of Pathology, Dr. Ivo PediπiÊ County
Hospital, Sisak;
3Department of Urology, Sestre milosrdnice University
Hospital, Zagreb, Croatia
The neoplastic cells of prostatic cancer often appear
pulled away from the surrounding stroma leaving halos
around the acini. These periacinar halos or so-called cleft-
like spaces are often observed, especially in Gleason grade
3 prostatic carcinoma.
As the accurate diagnosis of prostatic carcinoma in
needle core biopsies (NCBs) demands a sophisticated ap-
proach, there are many diagnostic criteria that should be
satisfied.
The aim of our study was to analyze prostatic NCBs in
order to determine the frequency of cleft-like spaces in tu-
mors and non-tumorous prostatic tissue. We analyzed 20
sextant NCBs that were performed at the Department of
Urology, Sestre milosrdnice University Hospital for clini-
cal suspicion of prostatic carcinoma (PSA > 4.0 ng/m and/
or DRE and TRUS positive). After a pathohistologic di-
agnosis of adenocarcinoma in NCB, prostatectomy was
performed. Specimens were fixed in 10% buffered formal-
dehyde, embedded in paraffin, cut at 5-µm thickness, and
routinely stained with hematoxylin and eosin. In some cases,
the material was stained with HMW-CK and alcian-PAS.
Prostatectomy specimens underwent step crosssections and
pathohistologic evaluation that confirmed the diagnosis of
adenocarcinoma. As a control group, we used NCBs of 20
patients in whom no cancer was found. Out of 20 patients
who were diagnosed as having prostatic adenocarcinoma in
at least one of NCB specimens, 14 (70%) had a NCB with
either focal or diffuse cleft-like spaces. In 5 (25%) cases,
clefts were incompletely defined or less pronounced, which
means that only half of acinus was circumscribed with
empty periacinar space in at least three glandular structures.
If each NCB specimen is considered as a sample per se, the
diagnosis of adenocarcinoma was made in 58 of the total
of 115 NCB samples. Concerning periacinar clefts, 23
(39.7%) specimens had clearly marked periacinar halos and
in 25 (43.1%) they were incompletely defined, but present.
In only 9 NCB specimens with the diagnosis of prostatic
carcinoma there were no cleft-like spaces around the tumor-
ous acini. In each of 20 cases, the prostatectomy specimens
contained adenocarcinoma.
In the control group, there were no well-defined clefts
observed in any of 119 NCB specimens. We conclude that
cleft-like spaces could be a useful additional criterion in
the diagnosis of prostatic adenocarcinoma in NCBs.
CORRELATION BEETWEN
NUCLEAR GRADE AND CELL TYPE
IN RENAL CELL CARCINOMA
S. KozloviÊ, M. TurËiÊ M. Fegeπ-BediÊ, A. Kopjar, M.
SladojeviÊ, H. »upiÊ, B. Kruπlin
Department of Pathology, General Hospital, Varaædin;
Department of Pathology, County Hospital, »akovec;
Ljudevit Jurak University Department of Pathology,
Sestre milosrdnice University Hospital, Zagreb, Croatia
There are several different clinical and pathologic prog-
nostic parameters in renal cell carcinoma (RCC) includ-
ing nuclear grade and cell type. However, many issues re-
garding these factors are still unresolved. The aim of this
study was to determine nuclear grade and cell type of
RCC, and to analyze their relationship.
Surgical pathology computer-based registry at Depart-
ment of Pathology, Sestre milosrdnice University Hospi-
tal, was canvassed for the period from January 1, 1998 to
December 31, 2001, to find all patients with RCC. Pa-
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tients with other primary tumors of the renal parenchyma
and pelvis were not included in the study. Nuclear grade
was determined according to Fuhrman et al. and WHO
classification, and cell types as proposed by Thoenes et al.
Nuclear grade was determined in the worst area of the
tumor. The predominant cell type was denoted as the cell
type.
In the examined period, there were 193 RCCs in 130
(67.3%) male and 63 (32.6%) female patients, age range
23-82 years. The tumors showed nuclear grade 2 in 95
(49.2%), grade 3 in 58 (30.1%), grade 4 in 21 (10.9%) and
grade 1 in 17 (8.8%) cases. There were two (1.0%) cases
of chromophobe RCC that were not graded. Clear cells
represented dominant cell type in 154 (79.8%), eosino-
philic cells in 31 (16.1%), spindle cells in 5 (2.6%), chro-
mophobe in two (1.0%) and basophilic in one tumor. In
the groups of nuclear grade 1 and 2 tumors, clear cells
represented dominant cell type in 102 (91.1%) cases, and
in groups 3 and 4 less than 57.0%.
The great majority of RCCs belong to nuclear grade
2 and 3 groups. In our study, the tumors composed of
eosinophilic cell type usually showed higher nuclear grade
than those of the clear cell type. Basophilic and chro-
mophobe cell types were very rarely observed. Our find-
ings suggest that eosinophilic and spindle cell types are as-
sociated with higher nuclear grade suggesting a more ag-
gressive behavior of these types of RCC.
EXPRESSION OF PROLIFERATING CELL
NUCLEAR ANTIGEN AND PROTEIN
PRODUCTS OF RETINOBLASTOMA AND
ADENOMATOUS POLYPOSIS COLI GENES
IN HUMAN FETAL TESTIS
S. MariÊ, F. BuliÊ-Jakuπ1, D. Jeæek2, G. JuriÊ-LekiÊ2,
M. Kos3, M. VlahoviÊ1
Dept. of Biology, Medical School, Osijek;
Dept. of Biology, Medical School, Zagreb, Dept. of
Histology and Embryology, Medical School, Zagreb;
Dept. of Pathology, Hospital for Obstetrics and
Gynecology, Medical School, Zagreb, Croatia
Proliferating cell nuclear antigen (PCNA) is a cofac-
tor necessary for the activity of DNA polymerase delta ex-
pressed in proliferating cells. Retinoblastoma (RB) and
adenomatous polyposis coli (APC) genes are tumor sup-
pressor genes whose protein products seem to have impor-
tant roles during development of different tissues and or-
gans. The purpose of this study was to investigate the ex-
pression of PCNA, RB and APC proteins in growing hu-
man fetal testis at the single cell level. Human testicular
tissue samples were archive biopsies from aborted fetuses
(18-27 weeks of gestation) obtained from the University
Department of Obstetrics and Gynecology, Zagreb, with
permission of the Ethics Committee of the same hospi-
tal. Tissue was routinely fixed in Bouin’s fixative and em-
bedded in paraffin. Serial sections (5 mm) were put on
silanized slides (DAKO, S 3003) and air-dried for 24
hours at room temperature. Samples were routinely
deparaffinized and hydrated and heated in a microwave
oven for 9 minutes at 620 W and 11 minutes at 310 W;
then, 3% H2O2 and a protein block were applied each for
5 minutes. Monoclonal Mouse Anti-PCNA, Clone PC
10, (M 0879, DAKO), was diluted to 1:50; Monoclonal
Mouse Anti-Human Retinoblastoma Gene Product,
Clone Rb1 (M 7131, DAKO), was diluted to 1:10 and
Monoclonal Mouse IgG, APC (OP80-100UG, Calbio-
chem) was diluted to 1:25. Negative control was a stan-
dard negative reagent (V 1617, DAKO). Samples were
treated with primary antibodies for 5 minutes and washed.
DAKO Catalysed Signal Amplification (CSA) System
Peroxidase was used for visualization of primary antibod-
ies according to the manufacturer’s instructions. Hema-
toxylin was used for counterstaining. PCNA, RB and
APC proteins were found in samples of testicular tissue
(18-27 weeks of gestation). PCNA was frequently expres-
sed in tubules (nuclei of Sertoli cells and prosperma-
togonia), and also in the surrounding peritubular and in-
terstitial cells. RB protein was found in testicular tubules
in prospermatogonia and Sertoli cells but was almost ab-
sent from the interstitium. APC protein was detected
rarely in the cytoplasm of prospermatogonia and intersti-
tial (Leydig) cells. We recorded cell-specific expression of
the endogenous proliferation marker (PCNA) and tumor
suppressor genes in growing fetal testis, which is impor-
tant for elucidation of their role in the normal development
of human testis.
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INCIDENCE OF PRIMARY MALIGNANT
TUMORS OF THE CENTRAL NERVOUS
SYSTEM IN THE 1991-2001 PERIOD
J. Talan-HraniloviÊ1, I. Novosel2, M. Belicza1, L. NegovetiÊ3
1Ljudevit Jurak University Department of Pathology,
Sestre milosrdnice University Hospital, Zagreb;
2Department of Pathology, Dr Ivo PediπiÊ County
Hospital, Sisak;
3Department of Neurosurgery, Sestre milosrdnice
University Hospital, Zagreb, Croatia
Among primary malignant intracranial tumors, malig-
nant gliomas have the highest incidence in all ethnic
groups, although there are differences in their prevalence.
The aim of the study was to analyze overall and his-
tology-specific trends in the prevalence of primary malig-
nant central nervous system (CNS) tumors in neurosur-
gical biopsy material at the Ljudevit Jurak University
Department of Pathology and Department of Neurosur-
gery, Sestre milosrdnice University Hospital during the
1991-2001 period. We analyzed tumor incidence accord-
ing to histologic type, age and sex. The aim was to show
whether there was an increase in the number of malignant
tumors of CNS, and in their incidence in younger age
groups and whether the rate of malignant tumors of CNS
showed a linear rise according to age and sex. The malig-
nant tumors of our interest were mostly glioblastomas and
anaplastic astrocytomas as they are most common of the
malignant tumors of CNS.
We analyzed the number of malignant tumors for each
year of the study period according to histologic diagno-
sis, age and sex. Median was determined for each age
group, as shown in the table and figure.
Study results showed that during the 1991-2001 pe-
riod there were 503 malignant tumors in neurosurgical bi-
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Fig. 1. Frequency of primary maligant CNS tumors in the 1991-
2001 period









Fig. 2. Frequency of glioblastoma according to sex in the 1991-2001
period
opsy material. Malignant tumors with the highest inci-
dence were glioblastomas with a frequency of 349 and ana-
plastic astrocytomas (astrocytoma grade III) with a fre-
quency of 81. The incidence rate according to sex in these
two histologic types was 184 in male and 165 in female
patients with glioblastoma, while anaplastic astrocytoma
was diagnosed in 56 male and 25 female patients. Other
histologic types considered had a lower incidence as ex-
pected: anaplastic ependymoma 13, anaplastic oligoden-
droglioma 3, anaplastic meningeoma 3, anaplastic heman-
giopericytoma 7, neuroblastoma 5, medulloblastoma 23,
choroid plexus carcinoma 3, anaplastic pilocytic astrocyto-
ma 4, sarcoma 2, gliosarcoma 5, germinoma 6 and pinea-
loblastoma 4 (Fig. 1).
The median age for glioblastomas, both female and
male patients, was 55.3 years, and for anaplastic astrocy-
toma 33.6 years. The youngest patient with glioblastoma
as the most frequent malignant tumor of CNS, was a male
aged 13, and the oldest was a female aged 83.
Summarized data imply an increase in the number of
malignant glial tumors, expecially during the last few years
of study period, with a slight but persistent male predomi-
nance.
The peak incidence of malignant glial tumors was in
2000 (Fig. 2). The most important result of this survey was
a slow linear decrease of age at onset for malignant glial
tumors, expecially in male population. Among patients
aged 20-40, glioblastoma was diagnosed in 8.3% of cases,
with an equal male to female ratio (14:13). Age median
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of anaplastic astrocytoma showed a twenty-year earlier
onset as compared to glioblastoma (Table 1).
Table 1. Frequency and age median for glioblastomas and astrocy-
tomas anaplasticum.
Age median Frequency Total
male female male female
glioblastoma 54.5 56,1 184 165 349
anaplastic
astrocytoma 34.5 32.7 56 25 81
The male to female ratio was almost equal except for
the years 1992 and 1995, when the rate in male was by
50% higher (the beginning and the end of the war). The
total number of glioblastomas showed a significant in-
crease in the post-war period, with a peak incidence re-
corded 5 years after the war. This could have been the
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Ganglioglioma of the cerebellum is a rare tumor of this
localization that is often difficult to diagnose preopera-
tively. To our knowledge, there are less than 20 reported
cases of this tumor in the literature. All gangliogliomas are
potentially malignant tumors due to their glial compo-
nent.We present a case of a 55-year-old woman, without
previous medical history. Upon admission to our Depart-
ment, in May 2000, neurologic examination revealed cer-
ebellar symptomatology and symptoms of elevated intrac-
ranial pressure. Preoperative CT scans showed a large le-
sion, 54x43 mm, in the left cerebellar hemisphere, com-
pressing the fourth ventricle with subsequent obstructive
hydrocephalus. She underwent surgery one day after ad-
mission and subtotal reduction of the tumor was done.
Pathohistologic analysis revealed a cerebellar ganglio-
glioma with marked pleomorphic ganglion cells, astroglial
cells and abundant Rosenthal fibers. Immunohistoche-
mically, the ganglion cells stained positive for NSE and
glial cells for GFAP. Postoperative MR scan revealed a re-
sidual tumorous lesion and second-act surgery was per-
formed after a one-month period. Pathohistologic exami-
nation showed the presence of polymorphic glial cells with
multiple mitoses and necroses pointing to cerebellar glio-
blastoma. Postoperative recovery was complicated with
hypertensive hydrocephalus and ventriculoperitoneostomy
was performed. The patient died two months after hos-
pital admission. None of the neuroradiologic studies could
establish the exact diagnosis. It was only reached by pa-
thohistologic analysis. This is a rare case of cerebellar
ganglioglioma with transformation to glioblastoma.
CEREBELLAR MEDULLOBLASTOMA
INVOLVING PINEAL REGION IN A
62-YEAR-OLD MALE. CASE REPORT
L. NegovetiÊ, T. Sajko, J. Talan-HraniloviÊ1, V. Beroπ
Department of Neurosurgery, 1Ljudevit Jurak University
Department of Pathology, Sestre milosrdnice University
Hospital, Zagreb, Croatia
Medulloblastoma is one of the most common primary
tumors of the central nervous system in children and un-
common in adult age. A case of a 62-year-old man with
medulloblastoma in the superior cerebellar and pineal re-
gion is described. In July 2000, a 62-year-old man was ad-
mitted to our Department with symptoms of elevated in-
tracranial pressure. Non-contrast CT scans revealed ob-
structive hydrocephalus and ventriculoperitoneostomy was
done. Postoperatively performed MRI showed a tumorous
lesion in the superior cerebellar region expanding toward
and consuming the pineal region. A metastatic tumor or
pinealoblastoma was suspected. The patient underwent
surgery and pathohistologic analysis revealed a desmoplastic
medulloblastoma. Medulloblastoma is an uncommon tu-
mor of the posterior fossa mainly found in children.
Medulloblastomas may be difficult to recognize in the eld-
erly because of their rarity and their histologic similarity to
common metastatic tumors. Medulloblastomas arising ear-
lier in life occur close to the midline, whereas those arising
later in life are located more laterally within a cerebellar
hemisphere. This case report presents an exceptional occur-
rence of medulloblastoma involving the superior cerebellar
and pineal region, in the late middle aged adult. Thus, it
does not correlate with the common, accepted hypothesis
concerning these tumors.
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EFFECT OF MORPHOLOGIC CELL TYPES ON
THE EXPRESSION OF BCL-2, KI-67 AND P-53
IN UVEAL MELANOMAS
A. Krvavica1, J. Talan-HraniloviÊ2, M. Belicza2
1Department of Pathology and Forensic Medicine,
General Hospital Zadar;
2Ljudevit Jurak University Department of Pathology,
Sestre milosrdnice University Hospital, Zagreb, Croatia
SUMMARY ∑ Uveal melanomas are known to be less
aggressive malignant tumors compared with melanoma of
other localizations but the same morphological character-
istics. We hypothesized that immunohistochemical deter-
mination of expression of the known proliferation mark-
ers bcl-2 and ki-67, and p-53 as a suppressor gene marker,
could better explain the biological behavior of uveal mela-
noma vs. melanoma of other localizations. Thirty cases of
primary uveal melanoma of two levels of invasion were
tested retrospectively for the presence of bcl-2, Ki-67 and
p-53 proteins with the indirect peroxidase-antiperoxidase
immunoenzyme method and three step ABC/AP method.
The intensity of reaction was assessed by semiquantiative
method.
Key words: bcl-2 oncoprotein, Ki-67 oncogene, p-53 su-
pressor gene, uveal melanoma
Introduction
Uveal melanomas consist of two distinct cell types,
spindle and epitheloid, having different clinical impli-
cations. These melanomas are known to be less aggressive
malignant tumors compared with the cutaneous type of
the same cell characteristics1. Although many factors are
important, cell type is of major prognostic significance.
The lesions composed completely or predominantly of
spindle cells are of low aggressiveness, do not tend to
metastasize, and permit about a 75% survival at 15 years.
In contrast, epitheloid melanomas have only 35% survival
at 15 years despite early enucleation. The bcl-2 onco-
protein plays a central role in programmed cell death in-
duced by p-53, acting as an inhibitor of the apoptotic pro-
cess, and it has given name to a family of proteins engaged
in promotion /inhibition of apoptosis. It is localized on
nuclear envelope, inner mitochondrial membrane and
rough endoplasmic reticulum. Bcl-2 in malignant mela-
noma may play a role in tumor development by sparing
the cells from apoptotic death and thereby exposing them
to secondary events2. Ki-67 antibody reacts with nuclear
antigen present in proliferating cells of various human
malignant tumors3. Ki-67 expression begins in the G1
phase of cell cycle, increases through S, G2 and M, and is
absent in G0 phase. It is a well established technique for
measuring cell proliferation in routinely processed, forma-
lin fixed, paraffin embedded tissue. Roles for p-53 have
been identified in aspects of DNA damage recognition,
DNA repair, cell cycle regulation, and most particularly in
triggering apoptosis after genetic injury. p-53 is the most
commonly mutated gene in human malignancy, prevalent
in cancers of a wide variety of histogenesis and primary
sites4.
Aims of the study
- to investigate the expression of bcl-2, Ki-67 and p-53
immunocomplexes in uveal melanoma cells;
- to examine whether the intensity of expression corre-
lates with morphological cell type
Material and Methods
Thirty cases of primary uveal melanoma were tested
for the presence of bcl-2, Ki-67 and p-53 proteins with
the indirect peroxidase-antiperoxidase immunoenzyme
method and three step ABC/AP method5. All cases were
diagnosed at the Sestre milosrdnice University Hospital
from Zagreb.
The pure epitheloid cell type was present in 5/30 mela-
nomas, whereas 13 were of spindle cell, and 12 a combina-
tion of epitheloid and spindle cell type. The intensity of
reaction was assessed by semiquantitative method: negative
(-); positive in <50% of cells (+); positive in 50% of cells (++);
and positive in >50% of cells (+++). Data were statistically
analyzed by Fisher’s exact test with p>0.05 as statistically
significant, and Stuart-Maxwell test for little samples, with
p<0.016.
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Results
Table 1. Expression of Ki-67 protein according to cell types
Ki-67 S M E Total
n % n % n % N %
- 3 10.0 1 3.3 4 13.3
+ 3 10.0 3 10.0
++ 6 20.0 6 20.0 3 10.0 15 50.0
+++ 1 3.3 6 20.0 1 3.3 8 26.7
Total 13 43.3 12 40.0 5 16.7 30 100.0
Table 2. Expression of p-53 protein according to cell types
p-53 S M E Total
n % n % n % N %
- 4 13.3 1 3.3 5 16.7
+ 2 6.7 1 3.3 1 3.3 4 13.3
++ 6 20.0 5 16.7 2 6.7 13 43.3
+++ 1 3.3 6 20.0 1 3.3 8 26.7
Total 13 43.3 12 40.0 5 16.7 30 100.0
Comparison between Ki-67 and p-53 protein expression
and morphological cell types showed no statistically sig-
nificant differences (Fisher’s exact test p>0.05).
Table 3. Expression of bcl-2 protein according to morphologic cell
types
bcl-2 S M E Total
n  % n % n % N  %
- 7 23.3 4 13.3 2 6.7 13 43.3
+ 3 10.0 1 3.3 2 6.7 6 20.0
++ 2 6.7 2 6.7 4 13.3
+++ 1 3.3 5 16.7 1 3.3 7 23.3
Total 13 43.3 12 40.0 1 16.7 30 100.0
S=spindle cells; M=mixed cell population; E=epitheloid cells
Comparison between bcl-2 expression and morpho-
logical cell types showed no statistically significant differ-
ences (Fisher’s exact test p>0.05).
Conclusion
The intensity of expression of the bcl-2, Ki-67 and p-
53 proteins in uveal melanoma did not vary with the
morphological cell type.
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Saæetak
UTJECAJ MORFOLO©KOG TIPA STANICA NA
EKSPRESIJU BCL-2, KI-67 I P-53
U UVEALNIM MELANOMIMA
Usprkos morfoloπkoj grai sliËnoj drugim melanomima,
poznato je da uvealni melanomi imaju daleko bolju prognozu
od melanoma drugih lokalizacija. Upravo stoga pretpostavili
smo da bi odreivanje ekspresije bcl-2, Ki-67 kao poznatih
Ëimbenika proliferacije, te p-53 proteina u stanicama uvealnih
melanoma moglo protumaËiti ovakvo bioloπko ponaπanje
uvealnih melanoma. U tu svrhu ispitano je retrogradno 30
primarnih uvealnih melanoma stadija pT2 i pT3 na prisutnost
bcl-2, Ki-67 i p-53 proteina indirektnom metodom peroksi-
daze-anti-peroksidaze i trofaznom metodom ABC/AP. Stupanj
reaktivnosti odreen je semikvantitativnom metodom.
KljuËne rijeËi: bcl-2 onkoprotein, Ki-67 onkogen, p-53 supre-
sorski gen, uvealni melanom
UNDIFFERENTIATED NASOPHARYNGEAL
CARCINOMA (LYMPHOEPITHELIOMA)
- A CASE REPORT
V. BlaæiËeviÊ, V. »aËinoviÊ, Æ. KotromanoviÊ
Department of Pathology and Forensic Medicine, Osijek
University Hospital, Osijek, Croatia
Undifferentiated nasopharyngeal carcinomas (lymphoe-
pithelioma) are quite common in some areas of the Orient,
but are rare in the USA and Europe. They often occur in
children and show a distinctly bimodal age distribution,
with peaks in the second and sixth decades. Survival corre-
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lates with the stage of disease. About 50%-80% of patients
are initially seen with cervical lymph node metastases from
an occult primary tumor. We report on four patients with
undifferentiated nasopharyngeal carcinoma (lymphoepithe-
lioma). Clinicopathologic features and treatment of this
tumor are discussed.
CHANGING TRENDS IN LYMPHOMA
INCIDENCE IN BIOPTIC MATERIAL IN
A 13-YEAR PERIOD (1989-2001)
L. PerkoviÊ1, D. Tomas2, S. »uriÊ-JuriÊ3, M. ©okËeviÊ3,
I. MariËeviÊ3, H. »upiÊ2
1Sveti Duh General Hospital
2Ljudevit Jurak University Department of Pathology and
3University Department of Cytology, Sestre milosrdnice
University Hospital, Zagreb, Croatia
The aim of our study was to determine the trends in
lymphoma incidence in bioptic material of all malignant
lymphomas diagnosed during a 13-year period (1989-
2001). Patient data were obtained from the files of the
Department of Cytology and computer based surgical pa-
thology registry at the Ljudevit Jurak University Depart-
ment of Pathology. A total of 187 patients were recorded
in the study period. The following data were reviewed:
cytologioc and histologic type and localization of lym-
phoma, and patient age and sex. All samples were routinely
stained with HE, histochemical stains (PAS, Gomori, Gi-
emsa, May-Grünwald-Giemsa), and analyzed by immuno-
histochemistry. During the 13-year period, there were 187
cases of lymphoma: 167 of non-Hodgkin lymphoma
(NHL) and 20 of Hodgkin disease (HD). There were 35
cases (30 NHL and 5 HD) in which both cytology and
histology were performed. We observed an increasing fre-
quency of lymphomas during the study period. In 1989,
there were 10 cases but the number increased to 25 in 2001.
Sex distribution showed no significant differences during
the 1989-2001 period. Age distribution showed the mean
age to increase in males from 48.0 to 54.4, and in females
from 41.0 to 69.5 years. In this preliminary study, we no-
ticed an increasing frequency of lymphomas during the 13-
year period, with sex distribution showing no significant dif-
ferences, and with a mean age increase. Comparison of cy-
tologic and pathohistologic diagnoses showed correlation
in the majority of cases.
















Table and Fig. 2. Comparison of NHL and Hodgkin´s disease, 1989-
2001























Acta clin Croat 2002; 41:135-186 Conference papers
182 Acta clin Croat, Vol. 41, No. 2, 2002










1. STRICKLAND AH, ARTHUR GE, MATTHEWS JP, BE-
RESFORD JA, LOWENTHAL RM .Increased survival in pa-
tients diagnosed with Hodgkin’s disease in Tasmania, 1972-
1992.Aust N Z J Med 1998;28:609-14.
2. LIU S, SEMENCIW R, WATERS C, WEN SW, MAO Y. Time
trends and sex patterns in Hodgkin’s disease incidence in Canada,
1970-1995.Can J Public Health 2000, 91:188-92.
3. McNALLY RJ, ROMAN E, CARTWRIGHT RA . Leukemias
and lymphomas: time trends in the UK, 1984-93.Cancer Causes
Control 1999, 10:35-42.
4. CANI MI, POLLAN M. Non-Hodgkin’s lymphomas and occupa-
tion in Sweden. Int Arch Occup Environ Health 2001;74:443-9.
INCIDENTAL MALIGNANT TUMORS
AT AUTOPSY DURING A 48-YEAR PERIOD
(1953-2000)
M. Elez, V. GladiÊ, H. Jurlina, T. LeniËek, M. GlasnoviÊ,
A. Husnjak, H. »upiÊ
Ljudevit Jurak University Department od Pathology,
Sestre milosrdnice University Hospital, Zagreb, Croatia
The aim of our study was to determine the frequency
of clinically non-diagnosed malignant tumors. We analyzed
retrospectively autopsy reports from the Ljudevit Jurak Uni-
versity Department of Pathology, University Hospital Sestre
milosrdnice, for a 48-year period (1953-2000). During this
period, there were a total of 31374 autopsies performed, of
which in 1059 incidental malignant tumors (IMT) were
found, which makes 3.4% of the total number. The lead-
ing primary sites of origin of IMT, found on autopsy were
the lungs and stomach, followed by the colon, liver, kidney,
pancreas and prostate in descending order. Malignant tu-
mors in other organs were found in smaller numbers. When
divided into age groups, the peak incidence occurred in the
seventh and eighth decade of life, when mortality and
morbidity are often associated with a large number of con-
current pathological processes, mainly with non-malignant
diseases that often mask the symptoms developed by IMT.
We completed our data with pTNM classification for the
1993-2000 period, which showed a surprisingly high num-
ber of advanced stages in which malignant tumors were
accidentally detected on autopsies (T2N2M1 was the most
frequent stage of pulmonary cancer, T2N1M1 in stomach
and prostate cancer, and T4N3M1 in colon cancer), which
is in agreement with previously published studies. The no-
ticeable decline in the average rate of autopsies throughout
the investigated period did not affect the incidence of in-
cidental malignant tumors (the lowest incidence was 2.8%
and highest 3.9%). The study showed a significant propor-
tion of advanced primary tumors that were detected on au-
topsy and which had not developed into a clinical disease.
It is a complex problem, which could be elucidated by ad-
ditional investigation and closer collaboration with clini-
cians.
EFFECT OF GREEN TEA ON FREE RADICAL
ACTIVITIES IN RAT TERATOMA
R. Klepac
Department of Biology, Zagreb University School of
Medicine, Zagreb, Croatia
Free radicals are different aggressive oxygen species which
have one unsaturated oxygen atom. They damage cell mac-
romolecules: DNA, proteins and lipids. Free radicals are as-
sociated with different chronic diseases such as cataract and
cancer. Many studies demonstrated that polyphenosis from
green tea depressed tumor growth and its development. In
this study, we transplanted seven-day rat embryos under the
kidney capsul. These embryos developed after two weeks into
teratoid tumors. One half of treated rats were given 2% so-
lution of green tea ad libitum. All rats were sacrificed after
three months. Green tea did not influence tumor growth. In
tumor mitochondria, green tea depressed the production of
superoxide anion (80%). Tea solution did not change the level
of lipid peroxidation, which is a characteristic parameter of
oxidative stress in tumor tissues. In tumor mitochondria,
green tea increased the antioxidative capacity level of GSH,
enzymatic activity of SOD and cytochrome c oxidase.These
results show that green tea increased antioxidative defense in
rat teratoma, which probably retarded tumor development.
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STUDY OF NUCLEATED RED BLOOD CELLS
IN EVALUATION OF FETAL ASPHYXIA
M. Elayoty, S. Aref, H. Abdelhady
Mansoura University Children Hospital, Mansoura, Egypt
The aim of the study was to determine whether a rela-
tionship exists between the presence of nucleated red blood
cells (NRBC), timing of perinatal asphyxia, and severity of
hypoxic neurologic impairment. Nucleated red blood cells
from 27 single full term asphyxiated neonates were com-
pared with cord blood NRBC of 30 full term non asphyxi-
ated newborns. Our patients were classified into 3 groups
according to the degree of neurologic impairment sugges-
tive of hypoxic ischemic encephalopathy (mild - group I,
moderate ∑ group II and severe ∑ group III). The first and
highest NRBC value and the time to NRBC disappearance
were assessed. Asphyxiated neonates exhibited a signifi-
cantly higher number of NRBC per 100 white blood cells
(median=120; range: 5-835) than did the control group
(median=1; range: 0-8) (p=0.001). Newborns with severe
neurologic impairment (group III) had significantly higher
cord blood NRBC than group II and I (p=0.001 each). The
time of NRBC clearance from peripheral blood was signifi-
cantly longer in group III than in group I and II patients
(median value of NRBC on day 7 day was 0.0 (range 0-10)
in group I; 11 (range: 0-80) in group II; and 122 (range 0-
500) in group III). Meconium stained amniotic fluid was
significantly more present in group III than in groups II and
I (p=0.001). Correlation studies revealed highly significant
positive correlations between cord blood NRBC, cord blood
pH, and degree of neurologic impairment (p=0.001 both).
In this limited study, counting of NRBC appeared to iden-
tify the presence of fetal asphyxia and correlated well with
the severity of asphyxia. The peak value of NRBC and the
time of clearance along with the presence of meconium
stained amniotic fluid can help in determining the time of
fetal injury. In general, the closer the birth to the asphyxia
event, the lower the number of NRBC.
IMMUNOGLOBULIN DEPOSITS IN SKIN
BIOPSIES OF PATIENTS WITH SYSTEMIC
CONNECTIVE TISSUE DISEASES
B. Bogoeva1, A. Pusevski2, S. Kostadinova1, G.
Petrusevska1
Institute of Pathology, Faculty of Medicine; Department
of Rheumatology, Skopje, Republic of Macedonia
The aim of the study was to find deposits of immu-
noglobulins in the analyzed skin biopsies of patients with
connective tissue diseases (CTD). Skin biopsies from 25
patients with CTD (15 with scleroderma, 5 dermatomyo-
sitis, 3 rheumatoid arthritis and 2 SLE) were analyzed his-
tologically and histochemically. All biopsies were stained
by HE, PAS and staining for elastic tissue (Weighert re-
sorcin fuchsin and Van Gieson). Histologic changes were
present in all skin biopsies. They were characterized by
swelling and degeneration of collagen fibers that became
eosinophilic. Capillaries and small vessels showed thick-
ening of the basal lamina, endothelial cell damage and
perivascular edema with lymphocytic infiltrates. Biopsies
were positive for PAS and elastic tissue staining. Skin bi-
opsies were tested with direct immunofluorescence tech-
nique for anti-human IgG, IgM and IgA. Granular or lin-
ear immunofluorescent deposits were found at the dermo-
epidermal junction (DEJ) in 10 cases with scleroderma,
1 dermatomyositis and 2 SLE. Deposits of immunoglo-
bulins were also found in the vessel walls of skin biopsies
in 5 cases with scleroderma, 2 dermatomyositis and 2 SLE.
Antinuclear antibodies (ANA) were analyzed by the in-
direct immunofluorescence technique using serum from
the same patients, 20 of which were positive. The fluores-
cence technique provides visual localization of the anti-
gen or antibodies fixed to tissues, and is a useful immu-
nohistochemical approach to the study of these diseases.
HISTOLOGIC VARIABILITY IN THE ILIAC
CREST BIOPSY OF POSTMENOPAUSAL AND
OSTEOPOROTIC WOMEN
P. Lozo1, D. Krpan2, A. Krvavica3, V. Kuπec4
1Lozo Health centar, Zadar;
2Sveti Duh General Hospital, Zagreb;
3Zadar General Hospital, Zadar;
4Clinical Institute of Laboratory Diagnosis, Zagreb
University Hospital Centre, Zagreb, Croatia
SUMMARY ∑ Many investigations have been carried
out on osteoporosis and showed this disorder in a new light.
The reduction in bone structure and dynamics points to the
etiology that may be of therapeutic significance. Today we still
do not know everything about the histomorphometric char-
acteristics of each metabolic disturbance and bone disease.
Bone biopsy and histomorphometry are not available for most
patients and that is the reason why a broad classification of
these reductions in osteoporosis and osteomalacia are widely
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accepted in clinical practice. New findings from this complex
domain are necessary to design a strategy in the evolution of
new therapeutic devices and drugs with the intention to de-
crease the high disability and mortality rate in the vulnerable
population of postmenopausal women.
Key words: osteoporosis, osteomalacia, metabolic bone dis-
eases, bone histomorphometry, postmenopause
Postmenopausal osteoporosis is the commonest type
of osteoporosis in clinical practice1. At the cellular level,
osteoporosis is the consequence of imbalance or uncou-
pling of osteoblastic bone deposition and osteoclastic bone
resorption2,3. Histomorphometric studies have demon-
strated considerable heterogeneity in the activity of bone
cells and bone turnover in osteoporosis. It is well estab-
lished that the diagnosis of osteoporosis and fracture risk
assessment are based on bone density measurement4,6.
Association of bone histology characteristics and their
impact on bone density remains to be elucidated and was
addressed in this study.
Forty-three postmenopausal women underwent tran-
siliac bone biopsy in the course of diagnostic procedures and
the following static histomorphometric parameters were
assessed by optical grid: bone volume, osteoblast and osteoid
surface, osteoid thickness and osteoclast surface. Bone min-
eral density (BMD) was measured by DEXA at the lum-
bar spine and hip.The published reference data for
histomorphometric indices were used for comparison of
own results. Data were analyzed according to normal,
osteopenic and osteoporotic BMD results, and showed no
difference for any of the histomorphometric parameters.
A subgroup of patients with increased osteoclast and
osteoblast/osteoid surface (14/43) were identified, and
among them those with reduced bone volume (4/43).
BMD and T-scores for lumbar spine and hip in these two
subgroups were lower but not statistically significantly
from those in patients with normal histomorphometric
parameters for bone volume, osteoclast, osteoblast and
osteoid surfaces (8/43).
These results support the existence of great histologic
variability of bone cell activity in the postmenopause and
osteoporosis.The lack of association of single or several
histomorphometric parameters indicating rate of turnover
with BMD was probably the consequence of a high vari-
ance and limited patient sample. In conclusion, evidence
for increased bone cell activity with or without reduced
bone volume might be encountered in postmenopausal
women with normal or reduced bone mineral density.
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Saæetak
HISTOLO©KA RAZLI»ITOST U KO©TANOJ
BIOPSIJI POSTMENOPAUZALNIH I
OSTEOPOROTI»NIH ÆENA
Brojna istraæivanja provedena posljednjih godina pokazala
su osteoporozu u novom svjetlu. Promjene u koπtanoj strukturi
i dinamici upuÊuju na etiologiju poremeÊaja, πto je od presudnog
znaËenja za lijeËenje bolesti. S obzirom na Ëinjenicu da joπ
uvijek malo znamo o histomorfometrijskim znaËajkama poje-
dinih metaboliËnih bolesti te da je biopsija kosti i histomor-
fometrija joπ uvijek teæe dostupna veÊem broju bolesnika, danas
se u kliniËkoj praksi uglavnom rabi kliniËka klasifikacija po
kojoj se one dijele u dvije πiroke kategorije: osteoporozu i
osteomalaciju. Nova saznanja iz ovoga podruËja su od presudne
vaænosti za planiranje buduÊe strategije razvoja novih terapijskih
sredstava i lijekova kako bi se smanjio visok postotak invaliditeta
i smrtnosti u osjetljivoj populaciji postmenopauzalnih æena.
KljuËne rijeËi: osteoporoza, osteomalacija, metaboliËne koπtane
bolesti, histomorfometrija kosti, postmenopauza
COMBINED HOMICIDE ∑ SUICIDE IN OSIJEK
COUNTY, EAST CROATIA
M. MarcikiÊ1, B. DumenËiÊ1, E. Matuzalem1,
K. MarjanoviÊ1, M. UgljareviÊ2
1Dept. of Forensic Medicine and Pathology, School of
Medicine, Josip Juraj Strossmayer University, Osijek
2Dept. of Pathology, General Hospital, Vukovar, Croatia
Homicide and suicide are closely intertwined in com-
bined homicide-suicide. These tragic acts generate much
public concern because in some cases, homicide-suicide
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involves annihilation of entire family. The phenomenon
is difficult to study in part because the perpetrator is dead.
The literature review addresses demographic variable and
proposes two classifications, one based on psychopathol-
ogy, and the other on the relationship between the of-
fender and the victim, and suggests a three dimensional
analytical approach to the understanding of homicide-
suicide: psychopathology and ego deficits of the perpetra-
tor, cumulative and precipitating stressors, and motivation
and vector of destructive urges against self and the other
victims. To further understand the nature of this tragic
phenomenon, the investigators systematically collected
data on all combined homicide-suicide events (n=11) that
occurred over a 15-year period (1987-2001) in the Osijek
County.
Combined homicide-suicide represented approximately
1% of suicide and 5% of homicide in the study period.
Consortial (64%) followed by filial (27%) type were the two
most common combined homicide-suicide types. Husband,
lover and boyfriend were typical offenders in consortial
homicide-suicide. A father killed his daughters and then
hanged himself. Another father simultaneously destroyed
his son and himself by hand grenade. In another case, a
suicidal mother killed her daughter and son. Only one case
could be delineated as adversarial homicide-suicide.The
same method of destruction was implemented on both the
victim and the perpetrator in consortial homicide-suicide.
The couple’s home and apartment were a common (57%)
milieu of this devastating act. Depression, alcoholism and
possessiveness were the personality traits equally present in
consortial perpetrators.
PROSTATIC CANCER MORTALITY IN
THE PRE- AND POST-PSA ERA:
THE TRIESTE EXPERIENCE
R. Bussani, D. Camilot, F. Bassan, F. Silvestri
Institute of Pathological Anatomy, c/o Ospedale
Maggiore, Trieste, Italy
The exponential increase of PSA determinations in the
Province of Trieste, the presence of only one Institute of
Pathological Anatomy, and the high autoptical rate allow
us to make a comparison between the biological evolution
of the prostatic neoplasms diagnosed in the period preced-
ing the introduction of PSA and those histologically evi-
denced precisely after more or less casual PSA evaluation.
All cases of prostate carcinoma diagnosed in our Institute
in the years 1989/1990 and during the 1997-1999 period
were histologically reviewed. Each patient was studied ac-
cording to biologic evolution and, if deceased and autop-
sied, there was reanalysis of the diagnostic report to deter-
mine the cause of death. The processed data showed a sig-
nificant increase in the incidence of prostate carcinoma in
recent years, which was particularly evident in younger sub-
jects and almost certain PSA-correlation often showing low
grade tumors (≤4). Besides death rate in the two periods
under study, strongly influenced by different follow-up
times, in the subjects who died and were autopsied there was
progressive reduction in T3 cases and an overall decrease in
deaths due to cancer. Although the observed data are ab-
solutely preliminary and susceptible to profound changes re-
garding rightful extension of the follow-up periods, we re-
corded an improvement in the biology of these neoplasms,
presumably related to the early diagnosis and consequent
possibility of surgical treatment in relatively young subjects
with low grade and low stage tumors.
DIFFUSE METASTATIC LEPTOMENINGEAL
MELANOMATOSIS AS THE FIRST CLINICAL
SIGN OF A CUTANEOUS MELANOMA
R. Bussani, D. Camilot, F. Bassan, F. Silvestri
Department of Pathological Anatomy, University of
Trieste, Trieste, Italy
A 64-year-old man was hospitalized for right hemipare-
sis and systemic hypertension (180/110). In the last two
months, the patient suffered from frequent episodes of
vomit without other symptoms and was treated with ant-
acids. His clinical history was characterized by diabetes
mellitus and ischemic cardiopathy. The general condition
of the patient rapidly worsened, and after five days he pre-
sented high fever, lethargy and dyspnea due to massive
bronchopneumonia. Neither intracranial hypertension nor
liquor alterations were found. Electroencephalographic
findings were nonspecific. Magnetic resonance imaging was
obtained using a 0.5 Tesla scanner. On contrast enhanced
T1 weighted images obtained with axial, coronal and sag-
ittal scans, a mild high intensity signal was noted on the
surface of the sulci. This feature, although mild, is repre-
sentative of meningeal enhancement. Two days later, the
patient went into coma and died. At autopsy, the brain
weighed 1580 grams. Leptomeninges of the brain and of
the spinal cord, cerebral cortex, ependyma of lateral ven-
tricles, and basal nuclei were diffusely and intensively
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brownish. Small black metastatic lesions were evident in the
pleural region and in the liver. Thorough examination of the
body revealed a small pigmented lesion (15 mm) on the left
shoulder. Histologic examination of the cutaneous lesion
showed nodular melanoma. Cerebral and spinal meninges
were extensively infiltrated by melanomatous cells which
diffusely spread along the perforating vessels into the cere-
bral cortex. Melanoma is the third most common cause of
cerebral metastases in most series. A very infrequent form
of metastatic diffusion to the meninges is the so called lep-
tomeningeal carcinomatosis, a pathological entity first de-
scribed by Eberth in 1870. The neurological symptoms in
the patient were probably due to the very extensive neoplas-
tic metastatization of the meninges and cerebral cortex. This
is, to our knowledge, the first case of leptomeningeal mela-
nomatosis in which magnetic resonance was done only few
days before the patient’s death. The radiographic feature
observed in our patient may be useful for future diagnosis
of this uncommon pathology.
